The O
-1 O
, O
-2 O
, O
and O
3-year O
QOL O
, O
3-year O
survival O
rate O
, O
and O
the O
survival O
life O
of O
dead O
children O
patients O
were O
observed O
. O

The O
purpose O
of O
this O
study O
was O
to O
investigate O
the O
impact O
of O
pilates O
exercises O
on O
physical O
performance O
, O
flexibility O
, O
fatigue O
, O
depression O
and O
quality O
of O
life O
in O
women O
who O
had O
been O
treated O
for O
breast O
cancer O
. O

Patients O
were O
randomized O
to O
receive O
treatment O
over O
4 O
consecutive O
days O
or O
over O
11 O
days O
. O

At B-Premise
a I-Premise
median I-Premise
follow-up I-Premise
of I-Premise
6.6 I-Premise
years I-Premise
, I-Premise
results I-Premise
for I-Premise
Sx I-Premise
+ I-Premise
Ax I-Premise
and I-Premise
Sx I-Premise
yielded I-Premise
similar I-Premise
DFS I-Premise
( I-Premise
6-year I-Premise
DFS I-Premise
, I-Premise
67 I-Premise
% I-Premise
v I-Premise
66 I-Premise
% I-Premise
";" I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
HR I-Premise
] I-Premise
Sx I-Premise
+ I-Premise
Ax/Sx I-Premise
, I-Premise
1.06 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.79 I-Premise
to I-Premise
1.42 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.69 I-Premise
) I-Premise
and I-Premise
OS I-Premise
( I-Premise
6-year I-Premise
OS I-Premise
, I-Premise
75 I-Premise
% I-Premise
v I-Premise
73 I-Premise
% I-Premise
";" I-Premise
HR I-Premise
Sx I-Premise
+ I-Premise
Ax/Sx I-Premise
, I-Premise
1.05 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.76 I-Premise
to I-Premise
1.46 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.77 I-Premise
) I-Premise
. I-Premise

There B-Premise
were I-Premise
no I-Premise
significant I-Premise
differences I-Premise
between I-Premise
the I-Premise
narrow I-Premise
gastric I-Premise
tube I-Premise
group I-Premise
( I-Premise
NGT I-Premise
group I-Premise
, I-Premise
n=52 I-Premise
) I-Premise
and I-Premise
the I-Premise
whole-stomach I-Premise
group I-Premise
( I-Premise
WS I-Premise
group I-Premise
, I-Premise
n=52 I-Premise
) I-Premise
with I-Premise
regard I-Premise
to I-Premise
patient I-Premise
and I-Premise
cancer I-Premise
characteristics I-Premise
, I-Premise
operative I-Premise
procedure I-Premise
, I-Premise
postoperative I-Premise
intensive I-Premise
care I-Premise
unit I-Premise
( I-Premise
ICU I-Premise
) I-Premise
hospitalisation I-Premise
, I-Premise
and I-Premise
overall I-Premise
survival I-Premise
at I-Premise
1 I-Premise
year I-Premise
. I-Premise

Le B-Claim
( I-Claim
y I-Claim
) I-Claim
is I-Claim
an I-Claim
attractive I-Claim
target I-Claim
since I-Claim
it I-Claim
is I-Claim
expressed I-Claim
by I-Claim
most I-Claim
NSCLC I-Claim
. I-Claim

Secondary O
endpoints O
were O
the O
PSQI O
component O
scores O
. O

Among B-Premise
responding I-Premise
patients I-Premise
, I-Premise
mean I-Premise
scores I-Premise
generally I-Premise
improved I-Premise
from I-Premise
time I-Premise
of I-Premise
response I-Premise
to I-Premise
end-of-treatment I-Premise
assessment I-Premise
, I-Premise
substantially I-Premise
driven I-Premise
by I-Premise
patients I-Premise
achieving I-Premise
complete I-Premise
response I-Premise
( I-Premise
CR I-Premise
) I-Premise
. I-Premise

Using O
validated O
instruments O
, O
we O
prospectively O
assessed O
QOL O
( O
even O
after O
completion O
of O
protocol O
treatment O
) O
as O
one O
of O
the O
secondary O
end O
points O
of O
the O
V325 O
phase O
III O
trial O
. O

This O
randomised O
multicentre O
trial O
was O
conducted O
to O
establish O
the O
optimal O
duration O
of O
palliative O
chemotherapy O
in O
advanced O
non-small-cell O
lung O
cancer O
( O
NSCLC O
) O
. O

We O
randomly O
assigned O
75 O
patients O
to O
usual O
care O
and O
227 O
patients O
to O
acupuncture O
plus O
usual O
care O
( O
random O
assignment O
of O
1:3 O
respectively O
) O
with O
minimization O
controlling O
for O
baseline O
general O
fatigue O
and O
maintenance O
treatment O
. O

Temozolomide O
( O
TMZ O
) O
is O
an O
alkylating O
agent O
licensed O
for O
treatment O
of O
high-grade O
glioma O
( O
HGG O
) O
. O

After O
initial O
response O
to O
anthracycline- O
or O
taxane-based O
induction O
chemotherapy O
, O
224 O
patients O
were O
randomly O
assigned O
: O
112 O
to O
high-dose O
cyclophosphamide O
, O
mitoxantrone O
, O
and O
carboplatin O
chemotherapy O
and O
ASCT O
( O
HDCT O
) O
, O
and O
112 O
to O
standard O
therapy O
( O
ST O
) O
. O

Analysing B-Premise
response I-Premise
to I-Premise
FUFA I-Premise
and I-Premise
FOLFIRI I-Premise
in I-Premise
the I-Premise
per I-Premise
protocol I-Premise
set I-Premise
( I-Premise
n=119 I-Premise
) I-Premise
after I-Premise
un-blinding I-Premise
TS I-Premise
in I-Premise
the I-Premise
data I-Premise
base I-Premise
revealed I-Premise
a I-Premise
trend I-Premise
to I-Premise
better I-Premise
overall I-Premise
response I-Premise
to I-Premise
FOLFIRI I-Premise
( I-Premise
9/19 I-Premise
, I-Premise
47 I-Premise
% I-Premise
) I-Premise
in I-Premise
TS I-Premise
high I-Premise
compared I-Premise
to I-Premise
FUFA I-Premise
( I-Premise
5/23 I-Premise
, I-Premise
22 I-Premise
% I-Premise
, I-Premise
p=0.077 I-Premise
) I-Premise
. I-Premise

Many O
women O
with O
breast O
cancer O
need O
psychological O
help O
to O
cope O
more O
effectively O
after O
treatment O
. O

Mixed B-Premise
effects I-Premise
models I-Premise
with I-Premise
adjustment I-Premise
for I-Premise
baseline I-Premise
values I-Premise
, I-Premise
study I-Premise
site I-Premise
, I-Premise
treatment I-Premise
at I-Premise
baseline I-Premise
, I-Premise
and I-Premise
age I-Premise
gave I-Premise
intervention I-Premise
effect I-Premise
estimates I-Premise
( I-Premise
intervention I-Premise
minus I-Premise
control I-Premise
) I-Premise
at I-Premise
12 I-Premise
weeks I-Premise
of I-Premise
129 I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
83 I-Premise
to I-Premise
176 I-Premise
) I-Premise
for I-Premise
metres I-Premise
walked I-Premise
in I-Premise
12 I-Premise
minutes I-Premise
, I-Premise
182 I-Premise
( I-Premise
75 I-Premise
to I-Premise
289 I-Premise
) I-Premise
for I-Premise
minutes I-Premise
of I-Premise
moderate I-Premise
intensity I-Premise
activity I-Premise
reported I-Premise
in I-Premise
a I-Premise
week I-Premise
, I-Premise
2.6 I-Premise
( I-Premise
1.6 I-Premise
to I-Premise
3.7 I-Premise
) I-Premise
for I-Premise
shoulder I-Premise
mobility I-Premise
, I-Premise
2.5 I-Premise
( I-Premise
1.0 I-Premise
to I-Premise
3.9 I-Premise
) I-Premise
for I-Premise
breast I-Premise
cancer I-Premise
specific I-Premise
subscale I-Premise
of I-Premise
quality I-Premise
of I-Premise
life I-Premise
, I-Premise
and I-Premise
4.0 I-Premise
( I-Premise
1.8 I-Premise
to I-Premise
6.3 I-Premise
) I-Premise
for I-Premise
positive I-Premise
mood I-Premise
. I-Premise

Results B-Premise
analysis I-Premise
revealed I-Premise
that I-Premise
OMWQ-HN I-Premise
( I-Premise
F I-Premise
= I-Premise
12.199 I-Premise
, I-Premise
df I-Premise
= I-Premise
6,1314 I-Premise
, I-Premise
p I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
and I-Premise
FACT-HN I-Premise
( I-Premise
p I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
scores I-Premise
were I-Premise
significantly I-Premise
lower I-Premise
in I-Premise
LLLT I-Premise
than I-Premise
placebo I-Premise
group I-Premise
patients I-Premise
. I-Premise

Patients O
completed O
QL O
indicators O
at O
baseline O
and O
at O
1 O
, O
3 O
, O
5 O
, O
7 O
, O
9 O
, O
and O
11 O
months O
. O

This B-Premise
was I-Premise
accompanied I-Premise
by I-Premise
a I-Premise
significant I-Premise
improvement I-Premise
in I-Premise
the I-Premise
physical I-Premise
function I-Premise
( I-Premise
31 I-Premise
% I-Premise
erlotinib I-Premise
v I-Premise
19 I-Premise
% I-Premise
placebo I-Premise
, I-Premise
P I-Premise
= I-Premise
.01 I-Premise
) I-Premise
, I-Premise
and I-Premise
global I-Premise
QOL I-Premise
( I-Premise
35 I-Premise
% I-Premise
v I-Premise
26 I-Premise
% I-Premise
, I-Premise
P I-Premise
< I-Premise
.0001 I-Premise
) I-Premise
. I-Premise

Primary O
analyses O
were O
done O
by O
intention O
to O
treat O
and O
were O
based O
on O
scale O
scores O
at O
4 O
weeks O
and O
8 O
weeks O
. O

The B-Claim
3-hour I-Claim
infusion I-Claim
of I-Claim
Taxol I-Claim
is I-Claim
safe I-Claim
when I-Claim
given I-Claim
with I-Claim
premedication I-Claim
and I-Claim
is I-Claim
associated I-Claim
with I-Claim
less I-Claim
neutropenia I-Claim
. I-Claim

Incorporation B-Claim
of I-Claim
docetaxel I-Claim
, I-Claim
as I-Claim
in I-Claim
DCF I-Claim
or I-Claim
with I-Claim
other I-Claim
active I-Claim
drug I-Claim
( I-Claim
s I-Claim
) I-Claim
, I-Claim
is I-Claim
a I-Claim
new I-Claim
therapy I-Claim
option I-Claim
for I-Claim
patients I-Claim
with I-Claim
untreated I-Claim
advanced I-Claim
gastric I-Claim
cancer I-Claim
. I-Claim

Cannabinoid-related O
toxicity O
was O
assessed O
every O
2 O
weeks O
. O

There B-Premise
was I-Premise
significant I-Premise
early I-Premise
attrition I-Premise
due I-Premise
to I-Premise
disease I-Premise
progression I-Premise
";" I-Premise
only I-Premise
61.5 I-Premise
% I-Premise
of I-Premise
patients I-Premise
were I-Premise
alive I-Premise
at I-Premise
2 I-Premise
months I-Premise
. I-Premise

OS O
and O
updated O
PFS O
data O
are O
presented O
using O
Kaplan-Meier O
curves O
and O
log-rank O
tests O
stratified O
for O
hormone O
receptor O
and O
visceral O
disease O
status O
. O

Baseline O
global O
health O
status O
scores O
were O
found O
to O
be O
similar O
between O
treatment O
groups O
( O
64.7 O
vs O
65.3 O
) O
. O

There B-Premise
were I-Premise
statistically I-Premise
significant I-Premise
improvements I-Premise
in I-Premise
outcome I-Premise
in I-Premise
the I-Premise
experimental I-Premise
group I-Premise
compared I-Premise
with I-Premise
control I-Premise
group I-Premise
at I-Premise
both I-Premise
8 I-Premise
and I-Premise
12 I-Premise
weeks I-Premise
( I-Premise
except I-Premise
as I-Premise
indicated I-Premise
) I-Premise
for I-Premise
POMS I-Premise
total I-Premise
mood I-Premise
disturbance I-Premise
( I-Premise
and I-Premise
its I-Premise
subscales I-Premise
of I-Premise
anxiety I-Premise
, I-Premise
depression I-Premise
[ I-Premise
8 I-Premise
weeks I-Premise
only I-Premise
] I-Premise
, I-Premise
anger I-Premise
[ I-Premise
12 I-Premise
weeks I-Premise
only I-Premise
] I-Premise
, I-Premise
vigor I-Premise
, I-Premise
fatigue I-Premise
, I-Premise
and I-Premise
confusion I-Premise
[ I-Premise
8 I-Premise
weeks I-Premise
only I-Premise
] I-Premise
) I-Premise
, I-Premise
FACT-B I-Premise
, I-Premise
FACT-ES I-Premise
, I-Premise
( I-Premise
and I-Premise
Functional I-Premise
Assessment I-Premise
of I-Premise
Cancer I-Premise
Therapy I-Premise
subscales I-Premise
of I-Premise
physical I-Premise
, I-Premise
social I-Premise
[ I-Premise
8 I-Premise
weeks I-Premise
only I-Premise
] I-Premise
, I-Premise
emotional I-Premise
, I-Premise
and I-Premise
functional I-Premise
well-being I-Premise
) I-Premise
, I-Premise
and I-Premise
WHO-5 I-Premise
. I-Premise

Quality B-Claim
of I-Claim
life I-Claim
is I-Claim
an I-Claim
important I-Claim
issue I-Claim
in I-Claim
pancreatic I-Claim
cancer I-Claim
patients I-Claim
. I-Claim

This B-Claim
study I-Claim
demonstrates I-Claim
the I-Claim
feasibility I-Claim
and I-Claim
effectiveness I-Claim
of I-Claim
a I-Claim
psycho-educational I-Claim
intervention I-Claim
, I-Claim
which I-Claim
can I-Claim
accelerate I-Claim
the I-Claim
reduction I-Claim
of I-Claim
those I-Claim
negative I-Claim
affects I-Claim
which I-Claim
are I-Claim
present I-Claim
at I-Claim
the I-Claim
end I-Claim
of I-Claim
treatment I-Claim
. I-Claim

With O
the O
exception O
of O
previous O
chemotherapy O
, O
the O
treatment O
groups O
were O
well O
balanced O
, O
both O
regarding O
treatment- O
and O
patient-related O
factors O
. O

Results B-Claim
showed I-Claim
a I-Claim
significant I-Claim
increase I-Claim
in I-Claim
pain I-Claim
knowledge I-Claim
in I-Claim
patients I-Claim
who I-Claim
received I-Claim
the I-Claim
Pain I-Claim
Education I-Claim
Program I-Claim
and I-Claim
a I-Claim
significant I-Claim
decrease I-Claim
in I-Claim
pain I-Claim
intensity I-Claim
. I-Claim

Adverse B-Premise
events I-Premise
in I-Premise
both I-Premise
groups I-Premise
included I-Premise
fatigue I-Premise
, I-Premise
diminished I-Premise
sexual I-Premise
function I-Premise
, I-Premise
and I-Premise
hot I-Premise
flushes I-Premise
. I-Premise

Fifty-five O
patients O
were O
randomized O
to O
receive O
epoetin O
alpha O
, O
and O
54 O
patients O
received O
no O
epoetin O
. O

In O
a O
secondary O
analysis O
of O
a O
randomized O
trial O
of O
supportive-expressive O
group O
therapy O
, O
125 O
women O
with O
metastatic O
breast O
cancer O
( O
MBC O
) O
completed O
a O
depression O
symptom O
measure O
( O
Center O
for O
Epidemiologic O
Studies-Depression O
Scale O
[ O
CES-D O
] O
) O
at O
baseline O
and O
were O
randomly O
assigned O
to O
a O
treatment O
group O
or O
to O
a O
control O
group O
that O
received O
educational O
materials O
. O

Patients O
with O
cancer O
( O
n O
= O
178 O
) O
who O
agreed O
to O
participate O
in O
the O
study O
were O
randomized O
to O
the O
intervention O
arm O
( O
n O
= O
89 O
) O
or O
the O
control O
arm O
( O
n O
= O
89 O
) O
. O

The B-Premise
difference I-Premise
in I-Premise
PFS I-Premise
between I-Premise
three I-Premise
and I-Premise
four I-Premise
cycles I-Premise
is I-Premise
-1.0 I-Premise
% I-Premise
( I-Premise
80 I-Premise
% I-Premise
confidence I-Premise
limit I-Premise
[ I-Premise
CL I-Premise
] I-Premise
, I-Premise
-3.8 I-Premise
% I-Premise
, I-Premise
+1.8 I-Premise
% I-Premise
) I-Premise
. I-Premise

Carboplatin/vinorelbine B-Claim
is I-Claim
well I-Claim
tolerated I-Claim
by I-Claim
elderly I-Claim
patients I-Claim
with I-Claim
extensive-stage I-Claim
NSCLC I-Claim
. I-Claim

Although B-Premise
quality I-Premise
of I-Premise
life I-Premise
was I-Premise
similar I-Premise
across I-Premise
the I-Premise
three I-Premise
treatment I-Premise
arms I-Premise
, I-Premise
the B-Premise
combination I-Premise
treatment I-Premise
was I-Premise
more I-Premise
toxic I-Premise
than I-Premise
the I-Premise
two I-Premise
drugs I-Premise
given I-Premise
singly I-Premise
. I-Premise

Due O
to O
concerns O
of O
fragility O
fracture O
, O
exercise O
is O
a O
perceived O
contraindication O
for O
prostate O
cancer O
patients O
with O
bone O
metastases O
. O

Primary O
endpoint O
was O
overall O
survival O
";" O
secondary O
endpoints O
were O
disease-free O
survival O
, O
response O
rate O
, O
toxicity O
, O
and O
quality O
of O
life O
. O

This O
phase O
III O
randomized O
trial O
compared O
two O
chemotherapy O
regimens O
, O
gemcitabine O
plus O
carboplatin O
and O
mitomycin O
, O
ifosfamide O
, O
and O
cisplatin O
, O
in O
chemotherapy-naive O
patients O
with O
advanced O
non-small-cell O
lung O
cancer O
( O
NSCLC O
) O
. O

All O
patients O
received O
neoadjuvant O
antiandrogen O
therapy O
. O

Follow-up O
time O
ranged O
from O
14 O
to O
56 O
months O
( O
median O
, O
33 O
months O
) O
. O

Analysis O
was O
by O
intention O
to O
treat O
. O

The B-Claim
combination I-Claim
of I-Claim
etoposide I-Claim
plus I-Claim
cisplatin I-Claim
( I-Claim
EP I-Claim
) I-Claim
is I-Claim
considered I-Claim
to I-Claim
be I-Claim
standard I-Claim
therapy I-Claim
for I-Claim
small-cell I-Claim
lung I-Claim
cancer I-Claim
( I-Claim
SCLC I-Claim
) I-Claim
. I-Claim

Patients B-Premise
with I-Premise
an I-Premise
objective I-Premise
tumor I-Premise
response I-Premise
reported I-Premise
better I-Premise
physical I-Premise
well-being I-Premise
( I-Premise
P I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
, I-Premise
mood I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
, I-Premise
functional I-Premise
performance I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
and I-Premise
less I-Premise
effort I-Premise
to I-Premise
cope I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
compared I-Premise
with I-Premise
the I-Premise
non-responders I-Premise
and I-Premise
stable I-Premise
disease I-Premise
patients I-Premise
. I-Premise

A B-Premise
decrease I-Premise
in I-Premise
transfusion I-Premise
requirement I-Premise
did I-Premise
not I-Premise
reach I-Premise
significance I-Premise
over I-Premise
all I-Premise
3 I-Premise
months I-Premise
, I-Premise
but I-Premise
there I-Premise
was I-Premise
a I-Premise
significant I-Premise
reduction I-Premise
in I-Premise
the I-Premise
percentage I-Premise
of I-Premise
patients I-Premise
transfused I-Premise
in I-Premise
the I-Premise
second I-Premise
and I-Premise
third I-Premise
months I-Premise
( I-Premise
27 I-Premise
% I-Premise
r-HuEPO I-Premise
vs. I-Premise
56 I-Premise
% I-Premise
placebo I-Premise
) I-Premise
and I-Premise
a I-Premise
trend I-Premise
toward I-Premise
reduction I-Premise
in I-Premise
the I-Premise
mean I-Premise
total I-Premise
number I-Premise
of I-Premise
units I-Premise
transfused I-Premise
( I-Premise
1.20 I-Premise
units I-Premise
r-HuEPO I-Premise
vs. I-Premise
2.02 I-Premise
units I-Premise
placebo I-Premise
) I-Premise
, I-Premise
suggesting I-Premise
a I-Premise
lag I-Premise
of I-Premise
1 I-Premise
month I-Premise
before I-Premise
r-HuEPO I-Premise
can I-Premise
affect I-Premise
the I-Premise
transfusion I-Premise
requirement I-Premise
. I-Premise

Survival O
status O
for O
all O
patients O
was O
determined O
from O
our O
own O
records O
and O
from O
three O
external O
sources O
: O
the O
Hamburg O
cancer O
registry O
, O
family O
doctors O
, O
and O
the O
general O
citizen O
registration O
offices O
. O

The O
National O
Surgical O
Adjuvant O
Breast O
and O
Bowel O
Project O
B-30 O
trial O
included O
menstrual O
history O
( O
MH O
) O
and O
quality-of-life O
( O
QOL O
) O
studies O
to O
compare O
treatments O
on O
these O
outcomes O
. O

The B-Claim
unroofing I-Claim
and I-Claim
marsupialization I-Claim
procedure I-Claim
provides I-Claim
more I-Claim
clinical I-Claim
benefits I-Claim
in I-Claim
the I-Claim
treatment I-Claim
of I-Claim
pilonidal I-Claim
disease I-Claim
than I-Claim
rhomboid I-Claim
excision I-Claim
and I-Claim
Limberg I-Claim
flap I-Claim
and I-Claim
should I-Claim
be I-Claim
considered I-Claim
the I-Claim
procedure I-Claim
of I-Claim
choice I-Claim
. I-Claim

Key O
end O
points O
were O
QoL O
at O
18 O
weeks O
, O
measured O
with O
EORTC O
Quality O
of O
Life O
Questionnaire O
( O
QLQ O
) O
-C30 O
and O
QLQ-LC13 O
, O
and O
overall O
survival O
. O

A O
clinical O
trial O
tests O
whether O
a O
psychological O
intervention O
for O
cancer O
patients O
can O
do O
so O
, O
and O
also O
tests O
two O
routes O
to O
achieve O
better O
health O
: O
( O
a O
) O
reducing O
patients O
' O
Emotional O
Distress O
, O
and/or O
( O
b O
) O
enhancing O
their O
functional O
immunity O
. O

Patients O
were O
randomized O
in O
a O
2:1 O
ratio O
( O
erlotinib O
, O
n O
= O
488 O
and O
placebo O
, O
n O
= O
243 O
) O
. O

If B-Premise
offered I-Premise
a I-Premise
choice I-Premise
, I-Premise
80 I-Premise
% I-Premise
of I-Premise
the I-Premise
patients I-Premise
prior I-Premise
to I-Premise
start I-Premise
and I-Premise
58 I-Premise
% I-Premise
of I-Premise
the I-Premise
patients I-Premise
after I-Premise
completion I-Premise
of I-Premise
the I-Premise
program I-Premise
indicated I-Premise
that I-Premise
they I-Premise
preferred I-Premise
the I-Premise
entire I-Premise
multidimensional I-Premise
program I-Premise
. I-Premise

The O
two O
purposes O
of O
the O
study O
were O
to O
describe O
the O
effectiveness O
of O
the O
program O
and O
to O
obtain O
information O
about O
patient O
preferences O
for O
multi O
or O
mono O
dimensional O
rehabilitation O
programs O
. O

Median B-Premise
survival I-Premise
with I-Premise
GC I-Premise
and I-Premise
PE I-Premise
was I-Premise
8.0 I-Premise
and I-Premise
8.1 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
. I-Premise

There O
is O
dearth O
of O
evidence O
regarding O
the O
effects O
of O
LLLT O
on O
patient O
's O
subjective O
experience O
of O
OM O
and O
QOL O
. O

We O
report O
, O
to O
our O
knowledge O
, O
the O
first O
randomized O
trial O
of O
procarbazine O
, O
lomustine O
, O
and O
vincristine O
( O
PCV O
) O
versus O
TMZ O
in O
chemotherapy-naive O
patients O
with O
recurrent O
HGG O
. O

Objective B-Premise
response I-Premise
rates I-Premise
were I-Premise
22.8 I-Premise
% I-Premise
( I-Premise
13 I-Premise
of I-Premise
57 I-Premise
) I-Premise
in I-Premise
E I-Premise
and I-Premise
8.9 I-Premise
% I-Premise
( I-Premise
5 I-Premise
of I-Premise
56 I-Premise
) I-Premise
in I-Premise
V I-Premise
( I-Premise
p I-Premise
= I-Premise
0.0388 I-Premise
) I-Premise
. I-Premise

The O
randomized O
, O
controlled O
BOLERO-2 O
( O
Breast O
Cancer O
Trials O
of O
Oral O
Everolimus O
) O
trial O
demonstrated O
significantly O
improved O
progression-free O
survival O
with O
the O
use O
of O
everolimus O
plus O
exemestane O
( O
EVE O
+ O
EXE O
) O
versus O
placebo O
plus O
exemestane O
( O
PBO O
+ O
EXE O
) O
in O
patients O
with O
advanced O
breast O
cancer O
who O
developed O
disease O
progression O
after O
treatment O
with O
nonsteroidal O
aromatase O
inhibitors O
. O

Drain B-Premise
usage I-Premise
, I-Premise
length I-Premise
of I-Premise
hospital I-Premise
stay I-Premise
, I-Premise
and I-Premise
time I-Premise
to I-Premise
resumption I-Premise
of I-Premise
normal I-Premise
day-to-day I-Premise
activities I-Premise
after I-Premise
surgery I-Premise
were I-Premise
statistically I-Premise
significantly I-Premise
lower I-Premise
in I-Premise
the I-Premise
sentinel I-Premise
lymph I-Premise
node I-Premise
biopsy I-Premise
group I-Premise
( I-Premise
all I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
, I-Premise
and I-Premise
axillary I-Premise
operative I-Premise
time I-Premise
was I-Premise
reduced I-Premise
( I-Premise
P I-Premise
= I-Premise
.055 I-Premise
) I-Premise
. I-Premise

To O
assess O
the O
effect O
of O
a O
multimodal O
group O
exercise O
intervention O
, O
as O
an O
adjunct O
to O
conventional O
care O
, O
on O
fatigue O
, O
physical O
capacity O
, O
general O
wellbeing O
, O
physical O
activity O
, O
and O
quality O
of O
life O
in O
patients O
with O
cancer O
who O
were O
undergoing O
adjuvant O
chemotherapy O
or O
treatment O
for O
advanced O
disease O
. O

Survival O
curves O
were O
calculated O
using O
the O
Kaplan-Meier O
method O
, O
and O
hazard O
ratios O
were O
estimated O
using O
the O
Cox O
proportional O
hazards O
model O
. O

All O
patients O
received O
etoposide O
and O
carboplatin O
every O
3 O
weeks O
for O
up O
to O
six O
cycles O
. O

After O
catheter O
removal O
, O
112 O
patients O
were O
randomized O
to O
receive O
rehabilitation O
and O
duloxetine O
( O
group O
A O
) O
or O
rehabilitation O
alone O
( O
group O
B O
) O
, O
for O
16 O
wk O
. O

Grade B-Premise
2-3 I-Premise
alopecia I-Premise
( I-Premise
68 I-Premise
% I-Premise
PE I-Premise
vs I-Premise
17 I-Premise
% I-Premise
GC I-Premise
) I-Premise
and I-Premise
nausea I-Premise
( I-Premise
43 I-Premise
% I-Premise
PE I-Premise
vs I-Premise
26 I-Premise
% I-Premise
GC I-Premise
) I-Premise
were I-Premise
more I-Premise
frequent I-Premise
with I-Premise
PE I-Premise
. I-Premise

Notably O
, O
ablation O
preparation O
using O
withdrawal O
of O
LT3 O
for O
2 O
weeks O
did O
not O
prevent O
development O
of O
profound O
hypothyroidism O
, O
as O
also O
occurred O
when O
LT4 O
alone O
was O
withdrawn O
for O
4 O
weeks O
. O

There B-Premise
was I-Premise
a I-Premise
significant I-Premise
difference I-Premise
in I-Premise
mean I-Premise
dysphagia I-Premise
grade I-Premise
between I-Premise
treatment I-Premise
arms I-Premise
6 I-Premise
weeks I-Premise
following I-Premise
treatment I-Premise
( I-Premise
P=0.046 I-Premise
) I-Premise
, I-Premise
with I-Premise
worse I-Premise
swallowing I-Premise
reported I-Premise
by I-Premise
rigid I-Premise
stent-treated I-Premise
patients I-Premise
( I-Premise
mean I-Premise
dysphagia I-Premise
score I-Premise
difference=-0.49 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
( I-Premise
CI I-Premise
) I-Premise
-0.10 I-Premise
to I-Premise
-0.89 I-Premise
, I-Premise
P=0.014 I-Premise
) I-Premise
. I-Premise

The B-Claim
effects I-Claim
of I-Claim
Pemetrexed I-Claim
and I-Claim
Gefitinib I-Claim
as I-Claim
second I-Claim
line I-Claim
therapy I-Claim
were I-Claim
similar I-Claim
, I-Claim
although B-Premise
with I-Premise
different I-Premise
AEs I-Premise
. I-Premise

Need B-Premise
for I-Premise
reintervention I-Premise
was I-Premise
19 I-Premise
, I-Premise
10 I-Premise
, I-Premise
and I-Premise
33 I-Premise
% I-Premise
in I-Premise
these I-Premise
groups I-Premise
, I-Premise
respectively I-Premise
( I-Premise
p I-Premise
= I-Premise
0.123 I-Premise
) I-Premise
. I-Premise

The B-Premise
rate I-Premise
of I-Premise
recurrence I-Premise
was I-Premise
9/74 I-Premise
( I-Premise
12.1 I-Premise
% I-Premise
) I-Premise
in I-Premise
the I-Premise
IV I-Premise
arm I-Premise
and I-Premise
6/92 I-Premise
( I-Premise
6.5 I-Premise
% I-Premise
) I-Premise
in I-Premise
the I-Premise
oral I-Premise
arm I-Premise
, I-Premise
respectively I-Premise
( I-Premise
P I-Premise
= I-Premise
.937 I-Premise
) I-Premise
. I-Premise

Excess B-Premise
limb I-Premise
size I-Premise
( I-Premise
circumference I-Premise
and I-Premise
water I-Premise
displacement I-Premise
) I-Premise
and I-Premise
excess I-Premise
water I-Premise
composition I-Premise
were I-Premise
reduced I-Premise
significantly I-Premise
in I-Premise
the I-Premise
bandage I-Premise
group I-Premise
";" I-Premise
excess B-Premise
circumference I-Premise
and I-Premise
excess I-Premise
water I-Premise
composition I-Premise
were I-Premise
reduced I-Premise
significantly I-Premise
in I-Premise
the I-Premise
tape I-Premise
group I-Premise
. I-Premise

The O
purpose O
of O
this O
pilot O
study O
was O
to O
examine O
the O
effects O
of O
a O
combined O
cardiorespiratory O
and O
resistance O
exercise O
training O
program O
of O
short O
duration O
on O
the O
cardiorespiratory O
fitness O
, O
strength O
endurance O
, O
task O
specific O
functional O
muscle O
capacity O
, O
body O
composition O
and O
quality O
of O
life O
( O
QOL O
) O
in O
women O
breast O
cancer O
survivors O
. O

The O
primary O
outcome O
was O
the O
feasibility O
of O
a O
large O
RCT O
, O
and O
all O
outcomes O
for O
a O
definitive O
trial O
were O
tested O
. O

The B-Claim
sequential I-Claim
addition I-Claim
of I-Claim
topotecan I-Claim
to I-Claim
carboplatin-paclitaxel I-Claim
did I-Claim
not I-Claim
result I-Claim
in I-Claim
superior I-Claim
overall I-Claim
response I-Claim
or I-Claim
progression-free I-Claim
or I-Claim
overall I-Claim
survival I-Claim
. I-Claim

A O
phase O
III O
randomized O
multicenter O
trial O
was O
planned O
to O
compare O
GEM O
( O
1,000 O
mg/m O
( O
2 O
) O
on O
days O
1 O
, O
8 O
, O
and O
15 O
every O
28 O
days O
) O
with O
PLD O
( O
40 O
mg/m O
( O
2 O
) O
every O
28 O
days O
) O
in O
ovarian O
cancer O
patients O
who O
experienced O
treatment O
failure O
with O
only O
one O
platinum/paclitaxel O
regimen O
and O
who O
experienced O
recurrence O
or O
progression O
within O
12 O
months O
after O
completion O
of O
primary O
treatment O
. O

Patients O
performed O
5 O
targeted O
swallowing O
exercises O
throughout O
their O
CRT O
and O
participated O
in O
weekly O
swallowing O
therapy O
sessions O
to O
promote O
adherence O
and O
accurate O
technique O
. O

There B-Premise
was I-Premise
a I-Premise
significant I-Premise
effect I-Premise
of I-Premise
group I-Premise
on I-Premise
women I-Premise
's I-Premise
perceptions I-Premise
of I-Premise
social I-Premise
support I-Premise
with I-Premise
those I-Premise
in I-Premise
the I-Premise
intervention I-Premise
group I-Premise
being I-Premise
more I-Premise
satisfied I-Premise
with I-Premise
the I-Premise
emotional I-Premise
support I-Premise
they I-Premise
received I-Premise
( I-Premise
p I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

One O
hundred O
and O
twenty-one O
patients O
were O
enrolled O
through O
ten O
Cancer O
and O
Leukemia O
Group O
B O
( O
CALGB O
) O
institutions O
";" O
100 O
patients O
had O
breast O
cancer O
and O
21 O
had O
colorectal O
cancer O
. O

The O
differences O
of O
gender O
, O
age O
, O
primary O
GI O
malignancies O
, O
and O
hematological O
and O
biochemical O
data O
between O
the O
two O
compared O
groups O
were O
not O
statistically O
significant O
( O
all O
P O
> O
0.05 O
) O
. O

We O
based O
the O
program O
on O
the O
CRF O
guidelines O
of O
the O
National O
Comprehensive O
Cancer O
Network O
( O
NCCN O
) O
and O
incorporated O
the O
transtheoretic O
model O
( O
TTM O
) O
. O

Symptom B-Premise
distress I-Premise
was I-Premise
significantly I-Premise
worse I-Premise
for I-Premise
the I-Premise
RP+RT I-Premise
arm I-Premise
compared I-Premise
with I-Premise
the I-Premise
RP I-Premise
alone I-Premise
arm I-Premise
, O
but B-Premise
the I-Premise
treatment I-Premise
arms I-Premise
did I-Premise
not I-Premise
differ I-Premise
with I-Premise
respect I-Premise
to I-Premise
other I-Premise
general I-Premise
measures I-Premise
of I-Premise
HRQL I-Premise
. I-Premise

The B-Premise
1-year I-Premise
PFS I-Premise
rates I-Premise
were I-Premise
16.7 I-Premise
% I-Premise
with I-Premise
gefitinib I-Premise
and I-Premise
2.8 I-Premise
% I-Premise
with I-Premise
GP I-Premise
( I-Premise
HR I-Premise
, I-Premise
1.198 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.944 I-Premise
to I-Premise
1.520 I-Premise
) I-Premise
. I-Premise

Median B-Premise
OS I-Premise
was I-Premise
13.8 I-Premise
months I-Premise
for I-Premise
arm I-Premise
1 I-Premise
versus I-Premise
14.4 I-Premise
months I-Premise
for I-Premise
arm I-Premise
2 I-Premise
( I-Premise
P I-Premise
=.4 I-Premise
) I-Premise
. I-Premise

The B-Claim
combination I-Claim
of I-Claim
radiotherapy I-Claim
plus I-Claim
6 I-Claim
months I-Claim
of I-Claim
androgen I-Claim
suppression I-Claim
provides I-Claim
inferior I-Claim
survival I-Claim
as I-Claim
compared I-Claim
with I-Claim
radiotherapy I-Claim
plus I-Claim
3 I-Claim
years I-Claim
of I-Claim
androgen I-Claim
suppression I-Claim
in I-Claim
the I-Claim
treatment I-Claim
of I-Claim
locally I-Claim
advanced I-Claim
prostate I-Claim
cancer I-Claim
. I-Claim

There B-Premise
were I-Premise
no I-Premise
group I-Premise
differences I-Premise
with I-Premise
respect I-Premise
to I-Premise
survival I-Premise
. I-Premise

Days O
1 O
, O
8 O
, O
and O
15 O
in O
28-day O
cycles O
";" O
G O
arm O
: O
G O
as O
in O
GE O
. O

There B-Premise
was I-Premise
no I-Premise
significant I-Premise
difference I-Premise
between I-Premise
groups I-Premise
in I-Premise
all I-Premise
outcome I-Premise
variables I-Premise
( I-Premise
P I-Premise
> I-Premise
0.05 I-Premise
) I-Premise
through I-Premise
the I-Premise
whole I-Premise
study I-Premise
period I-Premise
. I-Premise

Median B-Premise
overall I-Premise
survival I-Premise
times I-Premise
were I-Premise
8.3 I-Premise
, I-Premise
11.0 I-Premise
, I-Premise
and I-Premise
10.4 I-Premise
months I-Premise
for I-Premise
ECF I-Premise
, I-Premise
TC I-Premise
, I-Premise
and I-Premise
TCF I-Premise
, I-Premise
respectively I-Premise
. I-Premise

Patients O
were O
randomly O
assigned O
to O
GEM O
or O
GEM-CAP O
. O

Finally O
, O
change O
in O
self-efficacy O
for O
PA O
predicted O
PA O
at O
2-year O
follow-up O
. O

Before B-Premise
radiotherapy I-Premise
, I-Premise
84 I-Premise
% I-Premise
of I-Premise
patients I-Premise
reported I-Premise
erections I-Premise
adequate I-Premise
for I-Premise
intercourse I-Premise
at I-Premise
least I-Premise
a I-Premise
few I-Premise
times I-Premise
during I-Premise
the I-Premise
previous I-Premise
year I-Premise
. I-Premise

Newly O
diagnosed O
advanced O
cancer O
patients O
undergoing O
radiation O
therapy O
were O
randomized O
to O
active O
QOL O
intervention O
or O
control O
groups O
. O

Using O
validated O
instruments O
, O
we O
prospectively O
assessed O
QOL O
within O
the O
randomized O
FLOT65+ O
phase O
II O
trial O
. O

As O
health O
economic O
aspects O
have O
only O
been O
studied O
in O
general O
terms O
, O
we O
estimated O
the O
cost O
of O
GJJ O
and O
that O
of O
stent O
placement O
in O
such O
patients O
. O

Men O
with O
metastatic O
prostate O
cancer O
( O
n O
= O
161 O
) O
were O
randomized O
to O
receive O
either O
daily O
prednisone O
alone O
or O
mitoxantrone O
( O
every O
3 O
weeks O
) O
plus O
prednisone O
. O

The B-Premise
changes I-Premise
between I-Premise
baseline I-Premise
and I-Premise
months I-Premise
5 I-Premise
and I-Premise
7 I-Premise
, I-Premise
respectively I-Premise
, I-Premise
indicated I-Premise
improvement I-Premise
in I-Premise
responders I-Premise
but I-Premise
heterogeneous I-Premise
patterns I-Premise
in I-Premise
patients I-Premise
with I-Premise
SD I-Premise
( I-Premise
6m I-Premise
) I-Premise
. I-Premise

Concurrent O
validity O
of O
the O
mood O
linear O
analogue O
self-assessment O
was O
consistently O
confirmed O
across O
four O
language O
groups O
. O

One-year B-Premise
progression-free I-Premise
survival I-Premise
was I-Premise
0 I-Premise
% I-Premise
with I-Premise
FU I-Premise
versus I-Premise
10 I-Premise
% I-Premise
with I-Premise
FUP I-Premise
( I-Premise
log-rank I-Premise
test I-Premise
, I-Premise
P I-Premise
= I-Premise
0.0001 I-Premise
) I-Premise
. I-Premise

Efficacy O
was O
assessed O
after O
the O
completion O
of O
3 O
treatment O
cycles O
";" O
28.9 O
% O
of O
patients O
( O
22 O
of O
76 O
patients O
) O
responded O
( O
no O
CRs O
, O
1 O
PR O
, O
and O
21 O
SDs O
) O
. O

Within O
the O
FLOT65+ O
trial O
, O
a O
total O
of O
143 O
patients O
aged O
≥65 O
years O
were O
randomly O
allocated O
to O
receive O
biweekly O
oxaliplatin O
plus O
5-fluorouracil O
( O
5-FU O
) O
continuous O
infusion O
and O
folinic O
acid O
( O
FLO O
) O
or O
the O
same O
regimen O
in O
combination O
with O
docetaxel O
50 O
mg/m O
( O
2 O
) O
( O
FLOT O
) O
. O

CP B-Premise
resulted I-Premise
in I-Premise
more I-Premise
anastomotic I-Premise
leaks I-Premise
. I-Premise

The B-Premise
hazard I-Premise
ratio I-Premise
of I-Premise
death I-Premise
for I-Premise
patients I-Premise
receiving I-Premise
the I-Premise
combination I-Premise
treatment I-Premise
was I-Premise
1.17 I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
CI I-Premise
] I-Premise
= I-Premise
0.95 I-Premise
to I-Premise
1.44 I-Premise
) I-Premise
that I-Premise
of I-Premise
patients I-Premise
receiving I-Premise
vinorelbine I-Premise
and I-Premise
1.06 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
0.86 I-Premise
to I-Premise
1.29 I-Premise
) I-Premise
that I-Premise
of I-Premise
patients I-Premise
receiving I-Premise
gemcitabine I-Premise
. I-Premise

Maintenance B-Claim
treatment I-Claim
with I-Claim
erlotinib I-Claim
appears I-Claim
to I-Claim
be I-Claim
a I-Claim
useful I-Claim
option I-Claim
for I-Claim
the I-Claim
management I-Claim
of I-Claim
Asian I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
NSCLC I-Claim
without I-Claim
progression I-Claim
after I-Claim
first-line I-Claim
chemotherapy I-Claim
. I-Claim

Sunitinib O
has O
demonstrated O
antitumor O
activity O
in O
metastatic O
renal O
cell O
carcinoma O
( O
mRCC O
) O
when O
given O
at O
50 O
mg/d O
on O
a O
4-weeks-on O
2-weeks-off O
regimen O
. O

Most O
patients O
had O
visceral O
metastases O
, O
43 O
% O
had O
a O
disease-free O
interval O
less O
than O
12 O
months O
, O
and O
85 O
% O
had O
measurable O
disease O
. O

As O
patients O
with O
pancreas O
and O
periampullary O
cancer O
( O
PPC O
) O
experience O
improved O
survival O
rates O
and O
longevity O
, O
the O
focus O
shifts O
toward O
living O
life O
while O
surviving O
cancer O
. O

We O
conducted O
a O
randomized O
controlled O
trial O
in O
Edmonton O
, O
Alberta O
, O
Canada O
, O
between O
2005 O
and O
2008 O
that O
stratified O
122 O
lymphoma O
patients O
by O
major O
disease O
type O
and O
current O
treatment O
status O
and O
randomly O
assigned O
them O
to O
usual O
care O
( O
UC O
";" O
n O
= O
62 O
) O
or O
12 O
weeks O
of O
supervised O
aerobic O
exercise O
training O
( O
AET O
";" O
n O
= O
60 O
) O
. O

Interestingly B-Claim
, I-Claim
the I-Claim
QOL I-Claim
response I-Claim
analysis I-Claim
also I-Claim
showed I-Claim
that I-Claim
aggressive I-Claim
premedication I-Claim
regimens I-Claim
appear I-Claim
to I-Claim
ameliorate I-Claim
potential I-Claim
negative I-Claim
effects I-Claim
of I-Claim
DPPE I-Claim
on I-Claim
emesis I-Claim
and I-Claim
nausea I-Claim
as I-Claim
measured I-Claim
by I-Claim
patient I-Claim
assessed I-Claim
QOL I-Claim
. I-Claim

Randomized O
controlled O
trial O
conducted O
from O
November O
2003 O
through O
May O
2008 O
of O
322 O
patients O
with O
advanced O
cancer O
in O
a O
rural O
, O
National O
Cancer O
Institute-designated O
comprehensive O
cancer O
center O
in O
New O
Hampshire O
and O
affiliated O
outreach O
clinics O
and O
a O
VA O
medical O
center O
in O
Vermont O
. O

Both O
groups O
were O
well O
matched O
for O
age O
, O
gender O
, O
staging O
, O
adjuvant O
therapy O
, O
and O
mean O
follow-up O
. O

Chemotherapy B-Claim
can I-Claim
profoundly I-Claim
affect I-Claim
patients I-Claim
' I-Claim
quality I-Claim
of I-Claim
life I-Claim
( I-Claim
QOL I-Claim
) I-Claim
, I-Claim
yet O
few O
clinical O
trials O
in O
advanced O
cervical O
cancer O
have O
included O
QOL O
outcomes O
. O

Patients O
with O
breast O
cancer O
reporting O
treatment-induced O
menopausal O
symptoms O
( O
N=422 O
) O
were O
randomly O
assigned O
to O
CBT O
( O
n=109 O
) O
, O
PE O
( O
n=104 O
) O
, O
CBT/PE O
( O
n=106 O
) O
, O
or O
to O
a O
waiting O
list O
control O
group O
( O
n=103 O
) O
. O

Quality B-Premise
of I-Premise
life I-Premise
was I-Premise
well I-Premise
preserved I-Premise
in I-Premise
the I-Premise
euthyroid I-Premise
group I-Premise
, I-Premise
compared I-Premise
with I-Premise
the I-Premise
hypothyroid I-Premise
group I-Premise
, I-Premise
as I-Premise
demonstrated I-Premise
by I-Premise
their I-Premise
lower I-Premise
pretreatment I-Premise
scores I-Premise
on I-Premise
the I-Premise
Billewicz I-Premise
scale I-Premise
for I-Premise
hypothyroid I-Premise
signs I-Premise
and I-Premise
symptoms I-Premise
, I-Premise
27 I-Premise
+/- I-Premise
7 I-Premise
vs. I-Premise
18 I-Premise
+/- I-Premise
4 I-Premise
( I-Premise
P I-Premise
< I-Premise
0.0001 I-Premise
) I-Premise
and I-Premise
their I-Premise
significantly I-Premise
higher I-Premise
Short I-Premise
Form-36 I-Premise
Health I-Premise
Assessment I-Premise
Scale I-Premise
scores I-Premise
in I-Premise
five I-Premise
of I-Premise
eight I-Premise
categories I-Premise
. I-Premise

This O
study O
is O
the O
first O
large O
prospective O
RCT O
of O
sentinel O
node O
biopsy O
( O
SNB O
) O
compared O
with O
standard O
axillary O
treatment O
( O
level O
I-III O
axillary O
lymph O
node O
dissection O
or O
four O
node O
sampling O
) O
, O
which O
includes O
comprehensive O
and O
repeated O
quality O
of O
life O
( O
QOL O
) O
assessments O
over O
18 O
months O
. O

Tamoxifen B-Premise
reduced I-Premise
the I-Premise
risk I-Premise
of I-Premise
noninvasive I-Premise
breast I-Premise
cancer I-Premise
by I-Premise
50 I-Premise
% I-Premise
( I-Premise
two-sided I-Premise
P I-Premise
< I-Premise
.002 I-Premise
) I-Premise
. I-Premise

The O
primary O
outcome O
was O
the O
adjusted O
mean O
difference O
in O
HFNS O
problem O
rating O
( O
1-10 O
) O
between O
CBT O
and O
usual O
care O
groups O
at O
9 O
weeks O
after O
randomisation O
. O

No B-Premise
statistically I-Premise
significant I-Premise
differences I-Premise
in I-Premise
quality I-Premise
of I-Premise
life I-Premise
scores I-Premise
between I-Premise
arms I-Premise
were I-Premise
noted I-Premise
. I-Premise

The O
study O
included O
130 O
patients O
with O
no O
history O
of O
transurethral O
resection O
of O
the O
prostate O
before O
treatment O
, O
who O
had O
brachytherapy O
on O
one O
of O
two O
prospective O
randomized O
trials O
, O
with O
explicitly O
planned O
and O
executed O
urethral-sparing O
techniques O
( O
100-150 O
% O
minimum O
peripheral O
dose O
) O
using O
either O
103Pd O
or O
125I O
for O
clinical O
T1c-T2c O
prostate O
cancer O
. O

Biomarker O
expression O
was O
assessed O
by O
immunohistochemistry O
. O

Primary O
-- O
patients O
alive O
and O
without O
moderate O
or O
severe O
cough O
, O
chest O
pain O
, O
haemoptysis O
, O
or O
dyspnoea O
six O
months O
from O
randomisation O
, O
as O
recorded O
by O
clinicians O
. O

Multiple B-Premise
baseline I-Premise
factors I-Premise
, I-Premise
including I-Premise
Eastern I-Premise
Cooperative I-Premise
Oncology I-Premise
Group I-Premise
performance I-Premise
status I-Premise
of I-Premise
0 I-Premise
, I-Premise
nonvisceral I-Premise
disease I-Premise
, I-Premise
< I-Premise
three I-Premise
metastatic I-Premise
sites I-Premise
, I-Premise
and I-Premise
less I-Premise
time I-Premise
from I-Premise
initial I-Premise
diagnosis I-Premise
until I-Premise
random I-Premise
assignment I-Premise
, I-Premise
were I-Premise
associated I-Premise
with I-Premise
improved I-Premise
OS I-Premise
. I-Premise

Acupuncture B-Claim
is I-Claim
an I-Claim
effective I-Claim
intervention I-Claim
for I-Claim
managing I-Claim
the I-Claim
symptom I-Claim
of I-Claim
CRF I-Claim
and I-Claim
improving I-Claim
patients I-Claim
' I-Claim
quality I-Claim
of I-Claim
life I-Claim
. I-Claim

Questionnaire O
compliance O
was O
94 O
% O
at O
baseline O
, O
but O
it O
declined O
differentially O
( O
67 O
% O
v O
47 O
% O
for O
cetuximab O
v O
BSC O
at O
16 O
weeks O
) O
. O

Forty-two O
patients O
were O
randomized O
to O
receive O
misoprostol O
and O
41 O
to O
receive O
a O
placebo O
. O

The O
results O
were O
analyzed O
using O
a O
linear O
mixed-effects O
model O
. O

Results B-Claim
were I-Claim
comparable I-Claim
with I-Claim
or I-Claim
without I-Claim
a I-Claim
washout I-Claim
, I-Claim
supporting I-Claim
direct I-Claim
switching I-Claim
from I-Claim
anti-TNF I-Claim
therapy I-Claim
to I-Claim
abatacept I-Claim
as I-Claim
an I-Claim
option I-Claim
in I-Claim
clinical I-Claim
practice I-Claim
. I-Claim

Cetuximab B-Premise
preserved I-Premise
GHS I-Premise
at I-Premise
16 I-Premise
weeks I-Premise
( I-Premise
-0.2 I-Premise
v I-Premise
-18.1 I-Premise
";" I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
. I-Premise

Ancillary B-Premise
" I-Premise
on-treatment I-Premise
" I-Premise
analyzes I-Premise
showed I-Premise
that I-Premise
participants I-Premise
who I-Premise
recalled I-Premise
an I-Premise
exercise I-Premise
recommendation I-Premise
reported I-Premise
significantly I-Premise
more I-Premise
total I-Premise
exercise I-Premise
than I-Premise
participants I-Premise
who I-Premise
did I-Premise
not I-Premise
recall I-Premise
an I-Premise
exercise I-Premise
recommendation I-Premise
( I-Premise
mean I-Premise
difference I-Premise
, I-Premise
4.1 I-Premise
MET I-Premise
hr I-Premise
per I-Premise
week I-Premise
: I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
1.9-6.4 I-Premise
MET I-Premise
hr I-Premise
per I-Premise
week I-Premise
";" I-Premise
p I-Premise
< I-Premise
.001 I-Premise
) I-Premise
. I-Premise

A O
counseling O
intervention O
aimed O
at O
improving O
levels O
of O
sexual O
satisfaction O
and O
increasing O
successful O
utilization O
of O
medical O
treatment O
for O
erectile O
dysfunction O
( O
ED O
) O
was O
developed O
and O
pilot-tested O
for O
both O
the O
survivor O
of O
prostate O
carcinoma O
and O
his O
partner O
. O

Recent O
studies O
suggest O
acupuncture O
may O
be O
effective O
in O
reducing O
vasomotor O
symptoms O
in O
menopausal O
women O
. O

We B-Premise
observed I-Premise
no I-Premise
significant I-Premise
changes I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
. I-Premise

Hormonal B-Claim
breast I-Claim
cancer I-Claim
treatment I-Claim
increases I-Claim
menopausal I-Claim
symptoms I-Claim
in I-Claim
women I-Claim
. I-Claim

Standardized O
questionnaires O
at O
baseline O
, O
posttreatment O
, O
and O
at O
3-month O
and O
6-month O
follow-up O
assessed O
sexual O
function O
, O
marital O
adjustment O
, O
psychologic O
distress O
, O
and O
utilization O
of O
treatments O
for O
ED O
. O

Sertraline B-Claim
did I-Claim
not I-Claim
improve I-Claim
symptoms I-Claim
, I-Claim
wellbeing I-Claim
, I-Claim
or I-Claim
survival I-Claim
in I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
cancer I-Claim
who I-Claim
do I-Claim
not I-Claim
have I-Claim
major I-Claim
depression I-Claim
, I-Claim
and I-Claim
should I-Claim
be I-Claim
reserved I-Claim
for I-Claim
those I-Claim
with I-Claim
a I-Claim
proven I-Claim
indication I-Claim
. I-Claim

In O
total O
, O
126 O
patients O
from O
East O
and O
South-East O
Asian O
centers O
were O
randomized O
( O
14 O
% O
of O
the O
intent-to-treat O
population O
) O
: O
88 O
from O
Korea O
, O
28 O
from O
China O
and O
10 O
from O
Malaysia O
";" O
one O
patient O
was O
excluded O
from O
this O
analysis O
due O
to O
Indian O
ethnicity O
. O

All O
participants O
underwent O
assessment O
of O
physical O
activity O
, O
fitness O
, O
physical O
functioning O
, O
fatigue O
and O
exercise O
self-efficacy O
at O
baseline O
and O
after O
the O
16-week O
intervention O
. O

Thirty O
three O
patients O
( O
16 O
control O
, O
17 O
thalidomide O
) O
were O
evaluated O
at O
four O
weeks O
, O
and O
20 O
patients O
( O
eight O
control O
, O
12 O
thalidomide O
) O
at O
eight O
weeks O
. O

Thirty-two O
women O
with O
breast O
cancer O
were O
randomly O
assigned O
to O
scapula-oriented O
exercise O
group O
( O
n O
= O
16 O
) O
and O
general O
exercise O
group O
( O
n O
= O
16 O
) O
. O

Although B-Claim
it I-Claim
is I-Claim
premature I-Claim
to I-Claim
make I-Claim
any I-Claim
determination I-Claim
as I-Claim
to I-Claim
the I-Claim
efficacy I-Claim
of I-Claim
the I-Claim
interventions I-Claim
tested I-Claim
in I-Claim
this I-Claim
feasibility I-Claim
study I-Claim
, I-Claim
these B-Claim
results I-Claim
indicate I-Claim
that I-Claim
pursuing I-Claim
the I-Claim
III I-Claim
+ I-Claim
ISG I-Claim
model I-Claim
, I-Claim
as I-Claim
well I-Claim
as I-Claim
standard I-Claim
IIIs I-Claim
, I-Claim
may I-Claim
be I-Claim
fruitful I-Claim
areas I-Claim
of I-Claim
future I-Claim
research I-Claim
. I-Claim

A O
total O
of O
420 O
patients O
were O
randomised O
and O
411 O
were O
analysed O
. O

The O
intervention O
took O
place O
over O
a O
4-month O
period O
. O

A B-Claim
supervised I-Claim
multimodal I-Claim
exercise I-Claim
intervention I-Claim
including I-Claim
high I-Claim
and I-Claim
low I-Claim
intensity I-Claim
components I-Claim
was I-Claim
feasible I-Claim
and I-Claim
could I-Claim
safely I-Claim
be I-Claim
used I-Claim
in I-Claim
patients I-Claim
with I-Claim
various I-Claim
cancers I-Claim
who I-Claim
were I-Claim
receiving I-Claim
adjuvant I-Claim
chemotherapy I-Claim
or I-Claim
treatment I-Claim
for I-Claim
advanced I-Claim
disease I-Claim
. I-Claim

Grade B-Premise
3/4 I-Premise
neutropenia I-Premise
occurred I-Premise
in I-Premise
29 I-Premise
% I-Premise
of I-Premise
patients I-Premise
treated I-Premise
weekly I-Premise
and I-Premise
34 I-Premise
% I-Premise
of I-Premise
those I-Premise
treated I-Premise
once I-Premise
every I-Premise
3 I-Premise
weeks I-Premise
( I-Premise
P I-Premise
=.35 I-Premise
) I-Premise
. I-Premise

All O
patients O
received O
oral O
iron O
supplementation O
. O

Among B-Premise
these I-Premise
32 I-Premise
patients I-Premise
, I-Premise
8 I-Premise
had I-Premise
a I-Premise
partial I-Premise
response I-Premise
( I-Premise
intent-to-treat I-Premise
response I-Premise
rate I-Premise
, I-Premise
20 I-Premise
% I-Premise
) I-Premise
, I-Premise
and I-Premise
10 I-Premise
( I-Premise
25 I-Premise
% I-Premise
) I-Premise
had I-Premise
stable I-Premise
disease I-Premise
. I-Premise

Many B-Premise
patients I-Premise
( I-Premise
24 I-Premise
% I-Premise
) I-Premise
failed I-Premise
to I-Premise
complete I-Premise
at I-Premise
least I-Premise
6 I-Premise
weeks I-Premise
of I-Premise
therapy I-Premise
, I-Premise
including I-Premise
five I-Premise
( I-Premise
8 I-Premise
% I-Premise
) I-Premise
treatment-related I-Premise
early I-Premise
deaths I-Premise
. I-Premise

Medical B-Claim
effects I-Claim
were I-Claim
better I-Claim
after I-Claim
GJJ I-Claim
, O
although B-Claim
GJJ I-Claim
had I-Claim
higher I-Claim
total I-Claim
costs I-Claim
. I-Claim

In B-Premise
response I-Premise
to I-Premise
training I-Premise
, I-Premise
QOL I-Premise
, I-Premise
VO2peak I-Premise
( I-Premise
mean I-Premise
3.9 I-Premise
ml/kg/min I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.93 I-Premise
, I-Premise
6.90 I-Premise
) I-Premise
performance I-Premise
in I-Premise
leg I-Premise
press I-Premise
( I-Premise
17.9 I-Premise
kg I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
12.8 I-Premise
, I-Premise
22.4 I-Premise
) I-Premise
and I-Premise
sit-stand I-Premise
test I-Premise
( I-Premise
- I-Premise
0.67 I-Premise
s I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
- I-Premise
0.52 I-Premise
, I-Premise
- I-Premise
1.2 I-Premise
) I-Premise
improved I-Premise
( I-Premise
p I-Premise
< I-Premise
or I-Premise
= I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

After B-Premise
the I-Premise
rehabilitation I-Premise
program I-Premise
, I-Premise
cancer I-Premise
survivors I-Premise
( I-Premise
n=63 I-Premise
) I-Premise
displayed I-Premise
statistically I-Premise
significant I-Premise
improvements I-Premise
on I-Premise
health-related I-Premise
quality I-Premise
of I-Premise
life I-Premise
with I-Premise
effect I-Premise
sizes I-Premise
( I-Premise
ES I-Premise
) I-Premise
varying I-Premise
from I-Premise
0.38 I-Premise
to I-Premise
0.99 I-Premise
( I-Premise
RAND-36 I-Premise
) I-Premise
and I-Premise
from I-Premise
-0.34 I-Premise
to I-Premise
-0.57 I-Premise
( I-Premise
RSCL I-Premise
) I-Premise
, I-Premise
most I-Premise
persistent I-Premise
at I-Premise
3-month I-Premise
follow-up I-Premise
. I-Premise

The O
administration O
of O
the O
smallest O
possible O
amount O
of O
radioiodine O
would O
improve O
care O
. O

For B-Claim
treatment I-Claim
of I-Claim
advanced I-Claim
breast I-Claim
cancer I-Claim
, I-Claim
SFI I-Claim
can I-Claim
alleviate I-Claim
the I-Claim
bone I-Claim
marrow I-Claim
inhibition I-Claim
caused I-Claim
by I-Claim
chemotherapy I-Claim
, I-Claim
improve I-Claim
clinical I-Claim
symptoms I-Claim
and I-Claim
quality I-Claim
of I-Claim
life I-Claim
and I-Claim
prolong I-Claim
the I-Claim
survival I-Claim
period I-Claim
by I-Claim
regulating I-Claim
cellular I-Claim
immune I-Claim
function I-Claim
of I-Claim
patients I-Claim
, I-Claim
so I-Claim
as I-Claim
to I-Claim
enhance I-Claim
the I-Claim
therapeutic I-Claim
effect I-Claim
of I-Claim
chemotherapy I-Claim
. I-Claim

Immediate B-Premise
lung I-Premise
expansion I-Premise
did I-Premise
not I-Premise
correlate I-Premise
with I-Premise
radiologic I-Premise
recurrence I-Premise
, I-Premise
clinical I-Premise
recurrence I-Premise
, I-Premise
or I-Premise
complications I-Premise
( I-Premise
p I-Premise
= I-Premise
0.60 I-Premise
, I-Premise
0.15 I-Premise
, I-Premise
and I-Premise
0.20 I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

Significant B-Premise
differences I-Premise
of I-Premise
FACT-B I-Premise
score I-Premise
( I-Premise
p=0.008 I-Premise
) I-Premise
and I-Premise
FACT-G I-Premise
score I-Premise
( I-Premise
p=0.019 I-Premise
) I-Premise
were I-Premise
observed I-Premise
at I-Premise
that I-Premise
time I-Premise
point I-Premise
. I-Premise

There B-Premise
was I-Premise
no I-Premise
significant I-Premise
difference I-Premise
in I-Premise
any I-Premise
of I-Premise
the I-Premise
subjects I-Premise
revealed I-Premise
by I-Premise
the I-Premise
questionnaire I-Premise
regarding I-Premise
subjective I-Premise
or I-Premise
objective I-Premise
symptoms I-Premise
, I-Premise
or I-Premise
by I-Premise
the I-Premise
SF-8 I-Premise
between I-Premise
the I-Premise
daytime I-Premise
group I-Premise
and I-Premise
the I-Premise
nocturnal I-Premise
group I-Premise
after I-Premise
3 I-Premise
months I-Premise
of I-Premise
treatment I-Premise
. I-Premise

The O
primary O
outcome O
measure O
is O
quality-adjusted O
life O
years O
( O
QALYs O
) O
. O

An O
independent O
data O
monitoring O
committee O
reviewed O
all O
aspects O
of O
the O
trial O
. O

1442 O
patients O
were O
registered O
for O
the O
trial O
, O
of O
whom O
529 O
were O
randomly O
assigned O
to O
treatment O
groups O
and O
were O
included O
in O
our O
analysis O
( O
265 O
early O
, O
264 O
delayed O
) O
. O

Combined B-Claim
intrapleural I-Claim
therapy I-Claim
with I-Claim
bevacizumab I-Claim
and I-Claim
cisplatin I-Claim
was I-Claim
effective I-Claim
and I-Claim
safe I-Claim
in I-Claim
managing I-Claim
NSCLC-mediated I-Claim
MPE I-Claim
. I-Claim

Patients O
were O
followed O
up O
per-protocol O
";" O
there O
were O
no O
deaths O
, O
and O
five O
patients O
had O
a O
total O
of O
six O
complications O
. O

Psychological B-Claim
interventions I-Claim
are I-Claim
efficacious I-Claim
in I-Claim
reducing I-Claim
emotional I-Claim
distress I-Claim
for I-Claim
cancer I-Claim
patients I-Claim
. I-Claim

Assessments O
were O
done O
at O
baseline O
, O
9 O
weeks O
, O
and O
26 O
weeks O
after O
randomisation O
. O

Forty-one O
patients O
with O
unilateral O
breast-cancer-related O
lymphedema O
for O
at O
least O
3 O
months O
were O
randomly O
grouped O
into O
the O
DLT O
group O
( O
bandage O
group O
, O
N O
= O
21 O
) O
or O
the O
modified O
DLT O
group O
( O
K-tape O
group O
, O
N O
= O
20 O
) O
. O

The O
main O
objective O
of O
the O
study O
was O
to O
determine O
the O
benefits O
of O
psychosocial O
interventions O
for O
cancer O
patients O
who O
received O
RT O
. O

MBSR B-Claim
is I-Claim
recommended I-Claim
to I-Claim
support I-Claim
survivors I-Claim
of I-Claim
breast I-Claim
cancer I-Claim
. I-Claim

At B-Premise
a I-Premise
median I-Premise
follow-up I-Premise
of I-Premise
30 I-Premise
months I-Premise
, I-Premise
letrozole I-Premise
significantly I-Premise
improved I-Premise
disease-free I-Premise
survival I-Premise
( I-Premise
DFS I-Premise
";" I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
, I-Premise
the I-Premise
primary I-Premise
end I-Premise
point I-Premise
, I-Premise
compared I-Premise
with I-Premise
placebo I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
HR I-Premise
] I-Premise
for I-Premise
recurrence I-Premise
or I-Premise
contralateral I-Premise
breast I-Premise
cancer I-Premise
0.58 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
CI I-Premise
] I-Premise
0.45 I-Premise
, I-Premise
0.76 I-Premise
] I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
. I-Premise

This O
study O
compared O
the O
effect O
of O
two O
doses O
of O
pamidronate O
on O
health-related O
quality O
of O
life O
and O
skeletal O
morbidity O
in O
patients O
with O
newly O
diagnosed O
multiple O
myeloma O
. O

The O
subgroup O
analysis O
showed O
a O
better O
biochemical O
outcome O
for O
the O
higher O
dose O
group O
with O
an O
initial O
prostate-specific O
antigen O
level O
> O
15 O
ng/mL O
. O

Private O
medical O
clinic O
, O
Seattle O
, O
WA O
. O

Mean O
age O
was O
58 O
± O
10 O
years O
, O
57 O
% O
were O
female O
, O
and O
65 O
% O
were O
given O
palliative O
chemotherapy O
. O

We O
conducted O
a O
randomized O
trial O
comparing O
uterine-artery O
embolization O
and O
surgery O
in O
women O
with O
symptomatic O
uterine O
fibroids O
. O

A O
longitudinal O
QoL O
study O
on O
a O
subset O
of O
ESPAC-1 O
patients O
who O
prospectively O
completed O
the O
EORTC O
QLQ O
C-30 O
questionnaire O
during O
treatment O
and O
follow-up O
. O

Addition B-Claim
of I-Claim
temozolomide I-Claim
during I-Claim
and I-Claim
after I-Claim
radiotherapy I-Claim
for I-Claim
patients I-Claim
with I-Claim
newly I-Claim
diagnosed I-Claim
glioblastoma I-Claim
significantly I-Claim
improved I-Claim
survival I-Claim
without I-Claim
a I-Claim
negative I-Claim
effect I-Claim
on I-Claim
HRQOL I-Claim
. I-Claim

In B-Premise
limited I-Premise
disease I-Premise
the I-Premise
estimated I-Premise
percentages I-Premise
of I-Premise
survival I-Premise
at I-Premise
2 I-Premise
years I-Premise
were I-Premise
33 I-Premise
% I-Premise
in I-Premise
the I-Premise
early I-Premise
and I-Premise
24 I-Premise
% I-Premise
in I-Premise
the I-Premise
late I-Premise
alternating I-Premise
chemotherapy I-Premise
arms I-Premise
. I-Premise

Median B-Premise
progression-free I-Premise
survival I-Premise
( I-Premise
PFS I-Premise
) I-Premise
was I-Premise
4.57 I-Premise
months I-Premise
in I-Premise
E I-Premise
and I-Premise
2.53 I-Premise
months I-Premise
in I-Premise
V I-Premise
( I-Premise
p I-Premise
= I-Premise
0.0287 I-Premise
) I-Premise
, I-Premise
with I-Premise
an I-Premise
80.6 I-Premise
% I-Premise
increase I-Premise
in I-Premise
median I-Premise
PFS I-Premise
for I-Premise
E I-Premise
compared I-Premise
with I-Premise
V. I-Premise
Median B-Premise
survival I-Premise
time I-Premise
was I-Premise
11.67 I-Premise
months I-Premise
in I-Premise
E I-Premise
and I-Premise
9.3 I-Premise
months I-Premise
in I-Premise
V I-Premise
( I-Premise
p I-Premise
= I-Premise
0.6975 I-Premise
) I-Premise
. I-Premise

The O
purpose O
of O
our O
study O
is O
to O
compare O
the O
effectiveness O
of O
supportive O
care O
vs. O
3 O
intervention O
approaches O
, O
namely O
oral O
Etoposide O
, O
a O
3-drug O
combination O
, O
and O
radiotherapy O
using O
quality O
of O
life O
( O
QOL O
) O
as O
the O
primary O
measure O
of O
success O
. O

In O
contrast O
, O
coping B-Premise
strategies I-Premise
( I-Premise
MAC I-Premise
) I-Premise
were I-Premise
not I-Premise
significantly I-Premise
different I-Premise
between I-Premise
groups I-Premise
. I-Premise

Distress B-Premise
caused I-Premise
by I-Premise
these I-Premise
symptoms I-Premise
was I-Premise
reported I-Premise
significantly I-Premise
more I-Premise
often I-Premise
by I-Premise
men I-Premise
allocated I-Premise
radical I-Premise
prostatectomy I-Premise
than I-Premise
by I-Premise
men I-Premise
assigned I-Premise
to I-Premise
watchful I-Premise
waiting I-Premise
. I-Premise

A O
multicenter O
trial O
was O
conducted O
to O
determine O
the O
efficacy O
and O
toxicity O
of O
escalating O
dosages O
of O
liposomal O
tretinoin O
( O
all-trans-retinoic O
acid O
) O
administered O
once O
or O
three O
times O
weekly O
in O
patients O
with O
acquired O
immunodeficiency O
syndrome O
( O
AIDS O
) O
-associated O
Kaposi O
sarcoma O
. O

Combining B-Claim
bevacizumab I-Claim
with I-Claim
docetaxel I-Claim
and I-Claim
trastuzumab I-Claim
did I-Claim
not I-Claim
significantly I-Claim
improve I-Claim
investigator-assessed I-Claim
PFS I-Claim
. I-Claim

Taxol B-Premise
( I-Premise
paclitaxel I-Premise
";" I-Premise
Bristol-Myers I-Premise
Squibb I-Premise
, I-Premise
Wallingford I-Premise
, I-Premise
CT I-Premise
) I-Premise
is I-Premise
a I-Premise
new I-Premise
anticancer I-Premise
agent I-Premise
with I-Premise
activity I-Premise
in I-Premise
a I-Premise
number I-Premise
of I-Premise
human I-Premise
tumors I-Premise
, I-Premise
including I-Premise
epithelial I-Premise
ovarian I-Premise
cancer I-Premise
. I-Premise

The O
primary O
end O
points O
were O
body O
image O
and O
cosmesis O
. O

For O
each O
outcome O
measure O
, O
a O
repeated-measures O
analysis O
of O
variance O
model O
, O
which O
incorporated O
week O
0 O
measurements O
as O
a O
covariate O
, O
was O
used O
to O
compare O
treatment O
groups O
at O
8 O
and O
12 O
weeks O
. O

This O
study O
aims O
to O
examine O
the O
effectiveness O
of O
a O
self-management O
multimodal O
comprehensive O
coping O
strategy O
program O
( O
CCSP O
) O
on O
quality O
of O
life O
( O
QOL O
) O
among O
breast O
cancer O
patients O
1 O
year O
after O
treatment O
. O

The O
planned O
sample O
size O
was O
850 O
, O
estimated O
to O
result O
in O
334 O
deaths O
, O
which O
would O
provide O
90 O
% O
power O
to O
detect O
a O
difference O
in O
2-year O
survival O
rates O
of O
60 O
% O
v O
70 O
% O
for O
CIS O
versus O
TPZ/CIS O
, O
respectively O
( O
hazard O
ratio O
= O
0.69 O
) O
. O

Improvements B-Premise
in I-Premise
self-esteem I-Premise
observed I-Premise
with I-Premise
RET I-Premise
during I-Premise
breast I-Premise
cancer I-Premise
chemotherapy I-Premise
were I-Premise
maintained I-Premise
at I-Premise
6-month I-Premise
follow-up I-Premise
whereas O
reductions B-Premise
in I-Premise
anxiety I-Premise
not I-Premise
observed I-Premise
with I-Premise
AET I-Premise
during I-Premise
breast I-Premise
cancer I-Premise
chemotherapy I-Premise
emerged I-Premise
at I-Premise
6-month I-Premise
follow-up I-Premise
. I-Premise

Quality O
of O
life O
( O
QOL O
) O
was O
assessed O
. O

To O
study O
the O
effects O
of O
Fuzheng O
Jianpi O
Decoction O
( O
FJD O
) O
combined O
chemotherapy O
on O
the O
quality O
of O
life O
( O
QOL O
) O
and O
the O
survival O
time O
of O
children O
with O
solid O
tumor O
. O

Vasomotor O
symptoms O
are O
common O
adverse O
effects O
of O
antiestrogen O
hormone O
treatment O
in O
conventional O
breast O
cancer O
care O
. O

Surgical O
resection O
is O
regarded O
as O
the O
only O
curative O
option O
for O
resectable O
oesophageal O
cancer O
, O
but O
pulmonary O
complications O
occurring O
in O
more O
than O
half O
of O
patients O
after O
open O
oesophagectomy O
are O
a O
great O
concern O
. O

These B-Premise
effects I-Premise
remained I-Premise
when I-Premise
statistically I-Premise
controlling I-Premise
for I-Premise
baseline I-Premise
levels I-Premise
of I-Premise
distress I-Premise
, I-Premise
immunity I-Premise
, I-Premise
and I-Premise
health I-Premise
as I-Premise
well I-Premise
as I-Premise
sociodemographic I-Premise
, I-Premise
disease I-Premise
, I-Premise
and I-Premise
cancer I-Premise
treatment I-Premise
variables I-Premise
. I-Premise

Change B-Premise
in I-Premise
self-efficacy I-Premise
for I-Premise
fat I-Premise
restriction I-Premise
partially I-Premise
accounted I-Premise
for I-Premise
the I-Premise
intervention I-Premise
's I-Premise
impact I-Premise
on I-Premise
overall I-Premise
diet I-Premise
quality I-Premise
among I-Premise
men I-Premise
only I-Premise
( I-Premise
mean I-Premise
indirect I-Premise
effect I-Premise
= I-Premise
0.60 I-Premise
) I-Premise
. I-Premise

Few O
intervention O
programs O
assist O
patients O
and O
their O
family O
caregivers O
to O
manage O
advanced O
cancer O
and O
maintain O
their O
quality O
of O
life O
( O
QOL O
) O
. O

The B-Premise
rate I-Premise
of I-Premise
grade I-Premise
2 I-Premise
or I-Premise
above I-Premise
nausea I-Premise
was I-Premise
numerically I-Premise
higher I-Premise
in I-Premise
the I-Premise
GP I-Premise
arm I-Premise
, I-Premise
but B-Premise
the I-Premise
difference I-Premise
was I-Premise
not I-Premise
statistically I-Premise
significant I-Premise
( I-Premise
GE I-Premise
15.5 I-Premise
% I-Premise
, I-Premise
GP I-Premise
27.7 I-Premise
% I-Premise
, I-Premise
p I-Premise
= I-Premise
0.20 I-Premise
) I-Premise
. I-Premise

Randomized O
, O
double-blinded O
, O
placebo-controlled O
trial O
. O

The B-Claim
use I-Claim
of I-Claim
home-based I-Claim
assessments I-Claim
by I-Claim
a I-Claim
research I-Claim
nurse I-Claim
proved I-Claim
to I-Claim
be I-Claim
an I-Claim
effective I-Claim
way I-Claim
of I-Claim
obtaining I-Claim
high-quality I-Claim
data I-Claim
. I-Claim

On B-Claim
the I-Claim
basis I-Claim
of I-Claim
our I-Claim
trial I-Claim
and I-Claim
the I-Claim
meta-analysis I-Claim
, I-Claim
GEM-CAP I-Claim
should I-Claim
be I-Claim
considered I-Claim
as I-Claim
one I-Claim
of I-Claim
the I-Claim
standard I-Claim
first-line I-Claim
options I-Claim
in I-Claim
locally I-Claim
advanced I-Claim
and I-Claim
metastatic I-Claim
pancreatic I-Claim
cancer I-Claim
. I-Claim

Two-hundred O
seventeen O
of O
425 O
therapeutic O
trial O
patients O
were O
eligible O
and O
registered O
to O
the O
HRQL O
study O
. O

However B-Claim
, I-Claim
monitoring I-Claim
the I-Claim
lymphocyte I-Claim
count I-Claim
is I-Claim
advisable I-Claim
. I-Claim

Our B-Claim
findings I-Claim
showed I-Claim
no I-Claim
evidence I-Claim
of I-Claim
a I-Claim
survival I-Claim
benefit I-Claim
with I-Claim
early I-Claim
treatment I-Claim
of I-Claim
relapse I-Claim
on I-Claim
the I-Claim
basis I-Claim
of I-Claim
a I-Claim
raised I-Claim
CA125 I-Claim
concentration I-Claim
alone I-Claim
, I-Claim
and B-Claim
therefore I-Claim
the I-Claim
value I-Claim
of I-Claim
routine I-Claim
measurement I-Claim
of I-Claim
CA125 I-Claim
in I-Claim
the I-Claim
follow-up I-Claim
of I-Claim
patients I-Claim
with I-Claim
ovarian I-Claim
cancer I-Claim
who I-Claim
attain I-Claim
a I-Claim
complete I-Claim
response I-Claim
after I-Claim
first-line I-Claim
treatment I-Claim
is I-Claim
not I-Claim
proven I-Claim
. I-Claim

The B-Premise
two I-Premise
groups I-Premise
were I-Premise
comparable I-Premise
, I-Premise
with I-Premise
low I-Premise
global I-Premise
QOL I-Premise
scores I-Premise
and I-Premise
significant I-Premise
symptom I-Premise
burden I-Premise
, I-Premise
especially I-Premise
pain I-Premise
and I-Premise
fatigue I-Premise
, I-Premise
after I-Premise
thoracotomy I-Premise
. I-Premise

Our B-Claim
findings I-Claim
suggest I-Claim
that I-Claim
an I-Claim
oncologist I-Claim
recommendation I-Claim
may I-Claim
increase I-Claim
exercise I-Claim
behavior I-Claim
in I-Claim
newly I-Claim
diagnosed I-Claim
breast I-Claim
cancer I-Claim
survivors I-Claim
, I-Claim
particularly I-Claim
if I-Claim
it I-Claim
is I-Claim
recalled I-Claim
1 I-Claim
week I-Claim
after I-Claim
the I-Claim
recommendation I-Claim
. I-Claim

Secondary O
end O
points O
included O
progression-free O
survival O
( O
PFS O
) O
, O
overall O
survival O
( O
OS O
) O
, O
adverse O
events O
( O
AEs O
) O
, O
and O
quality-of-life O
measures O
. O

Comparing B-Premise
the I-Premise
single- I-Premise
and I-Premise
multiple-fraction I-Premise
radiotherapy I-Premise
schedules I-Premise
, I-Premise
no I-Premise
differences I-Premise
were I-Premise
found I-Premise
in I-Premise
life I-Premise
expectancy I-Premise
( I-Premise
43.0 I-Premise
versus I-Premise
40.4 I-Premise
weeks I-Premise
, I-Premise
P I-Premise
=.20 I-Premise
) I-Premise
or I-Premise
quality-adjusted I-Premise
life I-Premise
expectancy I-Premise
( I-Premise
17.7 I-Premise
versus I-Premise
16.0 I-Premise
weeks I-Premise
, I-Premise
P I-Premise
=.21 I-Premise
) I-Premise
. I-Premise

Despite O
premature O
trial O
closure O
, O
our O
data O
provided O
valuable O
insights O
. O

There B-Premise
were I-Premise
no I-Premise
significant I-Premise
adverse I-Premise
effects I-Premise
associated I-Premise
with I-Premise
r-HuEPO I-Premise
. I-Premise

PVI B-Premise
5-FU I-Premise
+ I-Premise
MMC I-Premise
caused I-Premise
more I-Premise
overall I-Premise
haematological I-Premise
toxicity I-Premise
but I-Premise
CTC I-Premise
grades I-Premise
3/4 I-Premise
was I-Premise
increased I-Premise
only I-Premise
for I-Premise
thrombocytopaenia I-Premise
. I-Premise

Asymptomatic O
postmenopausal O
women O
who O
took O
adjuvant O
tamoxifen O
for O
2 O
to O
3 O
years O
for O
operable O
breast O
cancer O
with O
a O
double O
endometrial O
thickness O
greater O
than O
7 O
mm O
were O
randomized O
to O
20 O
mg O
tamoxifen O
or O
1 O
mg O
anastrozole O
for O
the O
remaining O
duration O
, O
totaling O
5 O
years O
. O

Three B-Premise
of I-Premise
the I-Premise
quality-of-life I-Premise
domains I-Premise
showed I-Premise
trends I-Premise
toward I-Premise
increases I-Premise
in I-Premise
the I-Premise
exercise I-Premise
group I-Premise
: I-Premise
physical I-Premise
functioning I-Premise
( I-Premise
P I-Premise
=.050 I-Premise
) I-Premise
, I-Premise
general I-Premise
health I-Premise
( I-Premise
P I-Premise
=.048 I-Premise
) I-Premise
, I-Premise
and I-Premise
vitality I-Premise
( I-Premise
P I-Premise
=.023 I-Premise
) I-Premise
. I-Premise

Few O
randomized O
trials O
have O
compared O
the O
survival O
benefit O
of O
interferon-alfa O
over O
controls O
in O
metastatic O
renal O
cell O
carcinoma O
, O
and O
none O
has O
been O
performed O
using O
interleukin-2 O
. O

Swallowing O
function O
was O
assessed O
with O
the O
Functional O
Oral O
Intake O
Scale O
( O
FOIS O
) O
and O
the O
Performance O
Status O
Scale O
for O
Head O
and O
Neck O
Cancer O
Patients O
( O
PSS-H O
& O
N O
) O
at O
baseline O
, O
immediately O
after O
CRT O
, O
and O
at O
3 O
, O
6 O
, O
9 O
, O
and O
12 O
months O
after O
CRT O
. O

The B-Premise
change I-Premise
in I-Premise
total I-Premise
FACT-B+4 I-Premise
scores I-Premise
( I-Premise
measuring I-Premise
global I-Premise
QOL I-Premise
) I-Premise
closely I-Premise
resembled I-Premise
the I-Premise
TOI I-Premise
results I-Premise
. I-Premise

There B-Premise
were I-Premise
no I-Premise
significant I-Premise
differences I-Premise
in I-Premise
either I-Premise
PFS I-Premise
or I-Premise
OS I-Premise
between I-Premise
IFN1 I-Premise
and I-Premise
IFN5 I-Premise
( I-Premise
median I-Premise
of I-Premise
3.7 I-Premise
months I-Premise
and I-Premise
median I-Premise
of I-Premise
3.4 I-Premise
months I-Premise
PFS I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
median I-Premise
of I-Premise
25.5 I-Premise
months I-Premise
and I-Premise
median I-Premise
of I-Premise
17.5 I-Premise
months I-Premise
OS I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

Treatment O
with O
somatostatin O
analogues O
slowed O
kidney O
growth O
in O
patients O
with O
polycystic O
kidney O
disease O
( O
PKD O
) O
and O
reduced O
liver O
and O
kidney O
volume O
in O
a O
PKD O
rodent O
model O
. O

All B-Premise
procedures I-Premise
were I-Premise
well I-Premise
tolerated I-Premise
by I-Premise
the I-Premise
patients I-Premise
. I-Premise

Ninety-nine O
patients O
who O
had O
UAE O
and O
eight O
patients O
who O
had O
myomectomy O
were O
analyzed O
. O

Treatments B-Premise
were I-Premise
well I-Premise
tolerated I-Premise
in I-Premise
the I-Premise
3 I-Premise
groups I-Premise
. I-Premise

Adjuvant B-Claim
immunotherapy I-Claim
with I-Claim
whole-cell I-Claim
lysate I-Claim
dendritic I-Claim
cell I-Claim
vaccine I-Claim
may I-Claim
improve I-Claim
short-term I-Claim
survival I-Claim
. I-Claim

DPPE B-Claim
( I-Claim
tesmilifene I-Claim
) I-Claim
plus I-Claim
doxorubicin I-Claim
( I-Claim
DOX I-Claim
) I-Claim
demonstrated I-Claim
a I-Claim
significant I-Claim
improvement I-Claim
in I-Claim
survival I-Claim
versus I-Claim
DOX I-Claim
in I-Claim
a I-Claim
phase I-Claim
III I-Claim
clinical I-Claim
trial I-Claim
in I-Claim
advanced I-Claim
breast I-Claim
cancer I-Claim
. I-Claim

The B-Claim
study I-Claim
results I-Claim
suggest I-Claim
that I-Claim
K-tape I-Claim
could I-Claim
replace I-Claim
the I-Claim
bandage I-Claim
in I-Claim
DLT I-Claim
, I-Claim
and I-Claim
it I-Claim
could I-Claim
be I-Claim
an I-Claim
alternative I-Claim
choice I-Claim
for I-Claim
the I-Claim
breast-cancer-related I-Claim
lymphedema I-Claim
patient I-Claim
with I-Claim
poor I-Claim
short-stretch I-Claim
bandage I-Claim
compliance I-Claim
after I-Claim
1-month I-Claim
intervention I-Claim
. I-Claim

On B-Claim
the I-Claim
basis I-Claim
of I-Claim
these I-Claim
findings I-Claim
, I-Claim
the I-Claim
policy I-Claim
of I-Claim
EOF I-Claim
should I-Claim
be I-Claim
used I-Claim
after I-Claim
a I-Claim
complex I-Claim
gynecologic I-Claim
oncologic I-Claim
laparotomy I-Claim
. I-Claim

An B-Claim
Internet-based I-Claim
education I-Claim
program I-Claim
based I-Claim
on I-Claim
NCCN I-Claim
guidelines I-Claim
and I-Claim
TTM I-Claim
may I-Claim
help I-Claim
patients I-Claim
manage I-Claim
CRF I-Claim
. I-Claim

Thirty O
days O
after O
the O
treatment O
, O
efficacy O
, O
toxicity O
, O
and O
adverse O
effects O
were O
assessed O
in O
both O
study O
groups O
. O

241 O
patients O
( O
121 O
GC O
, O
120 O
PE O
) O
were O
recruited O
, O
of O
which O
216 O
( O
90 O
% O
) O
had O
died O
. O

Subjects O
were O
randomized O
to O
receive O
either O
an O
individualized O
homeopathic O
single O
remedy O
, O
a O
homeopathic O
combination O
medicine O
, O
or O
placebo O
. O

In B-Premise
the I-Premise
bevacizumab I-Premise
group I-Premise
, I-Premise
the I-Premise
levels I-Premise
of I-Premise
VEGF I-Premise
in I-Premise
the I-Premise
pleural I-Premise
fluid I-Premise
were I-Premise
significantly I-Premise
lower I-Premise
compared I-Premise
to I-Premise
those I-Premise
of I-Premise
the I-Premise
cisplatin I-Premise
group I-Premise
after I-Premise
treatment I-Premise
, I-Premise
which I-Premise
showed I-Premise
greater I-Premise
efficacy I-Premise
( I-Premise
p I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
. I-Premise

We O
aimed O
to O
determine O
the O
effectiveness O
of O
a O
lay-administered O
tailored O
education O
and O
coaching O
( O
TEC O
) O
intervention O
( O
aimed O
at O
reducing O
pain O
misconceptions O
and O
enhancing O
self-efficacy O
for O
communicating O
with O
physicians O
) O
on O
cancer O
pain O
severity O
, O
pain-related O
impairment O
, O
and O
quality O
of O
life O
. O

HRQL O
was O
evaluated O
with O
the O
Short O
Form O
36-Item O
( O
SF-36 O
) O
questionnaire O
";" O
subscales O
from O
the O
European O
Organisation O
for O
Research O
and O
Treatment O
of O
Cancer O
( O
EORTC O
) O
PR25 O
module O
for O
bowel O
and O
bladder O
symptoms O
and O
the O
OV28 O
and O
CX24 O
modules O
for O
sexual O
symptoms O
";" O
and O
demographic O
questions O
. O

There B-Premise
were I-Premise
no I-Premise
differences I-Premise
in I-Premise
functional I-Premise
outcome I-Premise
, I-Premise
morbidity I-Premise
, I-Premise
or I-Premise
QOL I-Premise
between I-Premise
LRP I-Premise
and I-Premise
ORP I-Premise
. I-Premise

Dosing O
was O
reduced O
to O
25 O
mg/d O
in O
46 O
patients O
( O
43 O
% O
) O
due O
to O
grade O
3/4 O
AEs O
. O

There B-Premise
was I-Premise
no I-Premise
significant I-Premise
difference I-Premise
in I-Premise
scores I-Premise
at I-Premise
months I-Premise
9 I-Premise
and I-Premise
12 I-Premise
( I-Premise
P I-Premise
= I-Premise
.24 I-Premise
and I-Premise
P I-Premise
= I-Premise
.93 I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

Absolute B-Premise
change I-Premise
in I-Premise
arm I-Premise
volume I-Premise
at I-Premise
12 I-Premise
months I-Premise
was I-Premise
2.5 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
-0.40 I-Premise
to I-Premise
5.3 I-Premise
) I-Premise
in I-Premise
the I-Premise
treatment I-Premise
group I-Premise
compared I-Premise
to I-Premise
1.2 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
-2.8 I-Premise
to I-Premise
5.1 I-Premise
) I-Premise
in I-Premise
the I-Premise
placebo I-Premise
group I-Premise
. I-Premise

We O
also O
investigated O
the O
relationship O
between O
Functional O
Assessment O
of O
Cancer O
Therapy O
( O
FACT O
) O
scale O
scores O
and O
EQ-5D O
utilities O
. O

At B-Premise
6 I-Premise
and I-Premise
12 I-Premise
months I-Premise
, I-Premise
55 I-Premise
% I-Premise
and I-Premise
39 I-Premise
% I-Premise
of I-Premise
intervention I-Premise
patients I-Premise
had I-Premise
a I-Premise
50 I-Premise
% I-Premise
or I-Premise
greater I-Premise
reduction I-Premise
in I-Premise
depressive I-Premise
symptoms I-Premise
( I-Premise
SCL-20 I-Premise
) I-Premise
from I-Premise
baseline I-Premise
compared I-Premise
to I-Premise
34 I-Premise
% I-Premise
and I-Premise
20 I-Premise
% I-Premise
of I-Premise
usual I-Premise
care I-Premise
participants I-Premise
( I-Premise
P I-Premise
= I-Premise
0.003 I-Premise
and I-Premise
P I-Premise
= I-Premise
0.029 I-Premise
) I-Premise
. I-Premise

Response O
was O
evaluated O
4 O
weeks O
after O
the O
last O
cycle O
. O

Response B-Premise
rates I-Premise
were I-Premise
also I-Premise
significantly I-Premise
improved I-Premise
with I-Premise
docetaxel I-Premise
versus I-Premise
vinorelbine I-Premise
( I-Premise
22.7 I-Premise
% I-Premise
v I-Premise
9.9 I-Premise
% I-Premise
";" I-Premise
P I-Premise
= I-Premise
.019 I-Premise
) I-Premise
. I-Premise

The B-Premise
estimated I-Premise
treatment I-Premise
effects I-Premise
( I-Premise
intervention I-Premise
minus I-Premise
usual I-Premise
care I-Premise
) I-Premise
for I-Premise
all I-Premise
participants I-Premise
were I-Premise
a I-Premise
mean I-Premise
( I-Premise
SE I-Premise
) I-Premise
of I-Premise
4.6 I-Premise
( I-Premise
2 I-Premise
) I-Premise
for I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
P I-Premise
= I-Premise
.02 I-Premise
) I-Premise
, I-Premise
-27.8 I-Premise
( I-Premise
15 I-Premise
) I-Premise
for I-Premise
symptom I-Premise
intensity I-Premise
( I-Premise
P I-Premise
= I-Premise
.06 I-Premise
) I-Premise
, I-Premise
and I-Premise
-1.8 I-Premise
( I-Premise
0.81 I-Premise
) I-Premise
for I-Premise
depressed I-Premise
mood I-Premise
( I-Premise
P I-Premise
= I-Premise
.02 I-Premise
) I-Premise
. I-Premise

High B-Premise
baseline I-Premise
plasma I-Premise
vascular I-Premise
endothelial I-Premise
growth I-Premise
factor I-Premise
A I-Premise
( I-Premise
VEGF-A I-Premise
) I-Premise
concentrations I-Premise
were I-Premise
associated I-Premise
with I-Premise
greater I-Premise
bevacizumab I-Premise
benefit I-Premise
( I-Premise
not I-Premise
statistically I-Premise
significant I-Premise
) I-Premise
. I-Premise

The O
assessments O
were O
repeated O
again O
at O
1 O
year O
, O
and O
a O
quality O
of O
life O
questionnaire O
was O
added O
. O

This B-Claim
confirms I-Claim
that I-Claim
the I-Claim
two-drug I-Claim
combination I-Claim
NP I-Claim
is I-Claim
a I-Claim
reference I-Claim
treatment I-Claim
for I-Claim
metastatic I-Claim
NSCLC I-Claim
. I-Claim

If O
replicated O
in O
larger O
and O
more O
focused O
trials O
, O
aerobic O
exercise O
may O
be O
an O
attractive O
option O
to O
manage O
sleep O
dysfunction O
in O
patients O
with O
cancer O
because O
of O
its O
favorable O
safety O
profile O
and O
other O
documented O
health O
benefits O
. O

Randomisation O
was O
done O
in O
blocks O
of O
12-20 O
participants O
, O
stratifying O
by O
age O
( O
younger O
than O
50 O
years O
, O
50 O
years O
or O
older O
) O
, O
and O
was O
done O
with O
a O
computer-generated O
sequence O
. O

The O
Steering O
Committee O
closed O
the O
trial O
. O

Even O
though O
both B-Premise
treatment I-Premise
modalities I-Premise
resulted I-Premise
in I-Premise
significant I-Premise
decrease I-Premise
in I-Premise
the I-Premise
total I-Premise
arm I-Premise
volume I-Premise
( I-Premise
12.2 I-Premise
% I-Premise
decrease I-Premise
in I-Premise
Group I-Premise
II I-Premise
and I-Premise
14.9 I-Premise
% I-Premise
decrease I-Premise
in I-Premise
Group I-Premise
I I-Premise
) I-Premise
( I-Premise
p I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
, I-Premise
no B-Premise
significant I-Premise
difference I-Premise
( I-Premise
p=0.582 I-Premise
) I-Premise
was I-Premise
found I-Premise
between I-Premise
those I-Premise
two I-Premise
groups I-Premise
. I-Premise

Primary O
outcome O
measures O
assessed O
spiritual O
well-being O
and O
quality O
of O
life O
";" O
secondary O
outcomes O
included O
anxiety O
, O
depression O
, O
hopelessness O
, O
symptom O
burden O
, O
and O
symptom-related O
distress O
. O

When B-Premise
wound I-Premise
complication I-Premise
was I-Premise
included I-Premise
in I-Premise
the I-Premise
model I-Premise
, I-Premise
patients I-Premise
with I-Premise
complications I-Premise
had I-Premise
lower I-Premise
MSTS I-Premise
and I-Premise
TESS I-Premise
scores I-Premise
in I-Premise
the I-Premise
first I-Premise
2 I-Premise
years I-Premise
after I-Premise
treatment I-Premise
. I-Premise

Training B-Claim
oncologists I-Claim
in I-Claim
responding I-Claim
to I-Claim
patient-reported I-Claim
functional I-Claim
concerns I-Claim
may I-Claim
increase I-Claim
the I-Claim
impact I-Claim
of I-Claim
this I-Claim
intervention I-Claim
. I-Claim

Both B-Claim
measures I-Claim
were I-Claim
responsive I-Claim
";" I-Claim
out B-Premise
of I-Premise
24 I-Premise
changes I-Premise
over I-Premise
time I-Premise
, I-Premise
19 I-Premise
were I-Premise
in I-Premise
the I-Premise
expected I-Premise
direction I-Premise
for I-Premise
the I-Premise
linear I-Premise
analogue I-Premise
self-assessment I-Premise
scale I-Premise
( I-Premise
p I-Premise
< I-Premise
or I-Premise
= I-Premise
0.05 I-Premise
for I-Premise
9 I-Premise
of I-Premise
19 I-Premise
) I-Premise
and I-Premise
17 I-Premise
for I-Premise
the I-Premise
adjective I-Premise
checklist I-Premise
( I-Premise
p I-Premise
< I-Premise
or I-Premise
= I-Premise
0.05 I-Premise
for I-Premise
10 I-Premise
of I-Premise
17 I-Premise
) I-Premise
. I-Premise

The B-Premise
overall I-Premise
progression-free I-Premise
survival I-Premise
rate I-Premise
was I-Premise
53 I-Premise
% I-Premise
at I-Premise
1 I-Premise
year I-Premise
and I-Premise
17 I-Premise
% I-Premise
at I-Premise
3 I-Premise
years I-Premise
. I-Premise

Cross-over O
single-blind O
random O
clinical O
trial O
. O

Patients B-Premise
in I-Premise
the I-Premise
PCDE I-Premise
arm I-Premise
had I-Premise
a I-Premise
statistically I-Premise
significant I-Premise
higher I-Premise
frequency I-Premise
of I-Premise
combined I-Premise
complete I-Premise
plus I-Premise
partial I-Premise
responses I-Premise
compared I-Premise
with I-Premise
those I-Premise
in I-Premise
the I-Premise
EP I-Premise
arm I-Premise
( I-Premise
21 I-Premise
% I-Premise
plus I-Premise
55 I-Premise
% I-Premise
versus I-Premise
13 I-Premise
% I-Premise
plus I-Premise
48 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
P I-Premise
=.02 I-Premise
for I-Premise
difference I-Premise
in I-Premise
combined I-Premise
objective I-Premise
responses I-Premise
) I-Premise
. I-Premise

Statistically B-Premise
significantly I-Premise
higher I-Premise
global I-Premise
QOL I-Premise
scores I-Premise
were I-Premise
found I-Premise
in I-Premise
PLD-treated I-Premise
patients I-Premise
at I-Premise
the I-Premise
first I-Premise
and I-Premise
second I-Premise
postbaseline I-Premise
QOL I-Premise
assessments I-Premise
. I-Premise

In B-Premise
the I-Premise
-5 I-Premise
versus I-Premise
3-day I-Premise
comparison I-Premise
, I-Premise
the I-Premise
projected I-Premise
2-year I-Premise
PFS I-Premise
is I-Premise
88.8 I-Premise
% I-Premise
and I-Premise
89.7 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
( I-Premise
difference I-Premise
, I-Premise
-0.9 I-Premise
% I-Premise
, I-Premise
( I-Premise
80 I-Premise
% I-Premise
CL I-Premise
, I-Premise
-4.1 I-Premise
% I-Premise
, I-Premise
+2.2 I-Premise
% I-Premise
) I-Premise
. I-Premise

These B-Claim
findings I-Claim
suggest I-Claim
that I-Claim
ways I-Claim
of I-Claim
making I-Claim
this I-Claim
method I-Claim
of I-Claim
hair I-Claim
removal I-Claim
more I-Claim
widely I-Claim
available I-Claim
to I-Claim
women I-Claim
with I-Claim
facial I-Claim
hirsutism I-Claim
should I-Claim
be I-Claim
considered I-Claim
. I-Claim

The B-Premise
5-year I-Premise
biochemical I-Premise
+/- I-Premise
clinical I-Premise
relapse-free I-Premise
and I-Premise
overall I-Premise
survival I-Premise
was I-Premise
55.9 I-Premise
% I-Premise
and I-Premise
85.3 I-Premise
% I-Premise
respectively I-Premise
for I-Premise
all I-Premise
patients I-Premise
, I-Premise
and I-Premise
did I-Premise
not I-Premise
differ I-Premise
between I-Premise
the I-Premise
two I-Premise
schedules I-Premise
. I-Premise

A B-Premise
higher I-Premise
rate I-Premise
of I-Premise
persistent I-Premise
thyroid I-Premise
remnants I-Premise
was I-Premise
observed I-Premise
in I-Premise
the I-Premise
rhTSH I-Premise
arm I-Premise
, I-Premise
although B-Premise
in I-Premise
most I-Premise
cases I-Premise
uptake I-Premise
was I-Premise
< I-Premise
0.1 I-Premise
% I-Premise
and I-Premise
of I-Premise
no I-Premise
clinical I-Premise
significance I-Premise
. I-Premise

Finally O
, O
cancer O
progression O
time O
and O
toxicity O
reaction O
of O
the O
two O
groups O
were O
evaluated O
. O

These B-Premise
findings I-Premise
were I-Premise
associated I-Premise
with I-Premise
higher I-Premise
post-procedure I-Premise
pain I-Premise
scores I-Premise
in I-Premise
the I-Premise
SEMS I-Premise
patient I-Premise
group I-Premise
( I-Premise
mean I-Premise
difference I-Premise
of I-Premise
the I-Premise
European I-Premise
Organisation I-Premise
for I-Premise
Research I-Premise
and I-Premise
Treatment I-Premise
of I-Premise
Cancer I-Premise
QLQ I-Premise
C-30 I-Premise
pain I-Premise
symptom I-Premise
score I-Premise
at I-Premise
week I-Premise
1=11.13 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
: I-Premise
2.89-19.4 I-Premise
";" I-Premise
P=0.01 I-Premise
) I-Premise
. I-Premise

We O
did O
a O
multicentre O
, O
open-label O
, O
randomised O
controlled O
trial O
at O
five O
study O
centres O
in O
three O
countries O
between O
June O
1 O
, O
2009 O
, O
and O
March O
31 O
, O
2011 O
. O

Between-group B-Premise
differences I-Premise
in I-Premise
the I-Premise
primary I-Premise
outcomes I-Premise
were I-Premise
not I-Premise
significant I-Premise
at I-Premise
12 I-Premise
months I-Premise
, I-Premise
and B-Premise
no I-Premise
significant I-Premise
effects I-Premise
emerged I-Premise
on I-Premise
the I-Premise
secondary I-Premise
end I-Premise
points I-Premise
. I-Premise

The B-Premise
median I-Premise
duration I-Premise
of I-Premise
response I-Premise
was I-Premise
8.8 I-Premise
and I-Premise
8.3 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
, I-Premise
in I-Premise
Study I-Premise
A I-Premise
and I-Premise
Study I-Premise
B I-Premise
. I-Premise

The O
aim O
of O
this O
study O
was O
to O
compare O
the O
toxicity O
and O
efficacy O
of O
radiation O
therapy O
( O
RT O
) O
for O
localized O
carcinoma O
of O
the O
prostate O
, O
using O
a O
hypofractionated O
( O
55 O
Gy/20 O
fractions/4 O
weeks O
) O
vs. O
a O
conventionally O
fractionated O
( O
64 O
Gy/32 O
fractions/6.5 O
weeks O
) O
dose O
schedule O
. O

Furthermore B-Premise
, I-Premise
statistically I-Premise
significant I-Premise
improvements I-Premise
in I-Premise
exercise I-Premise
capacity I-Premise
and I-Premise
muscle I-Premise
force I-Premise
of I-Premise
upper I-Premise
and I-Premise
lower I-Premise
extremities I-Premise
were I-Premise
displayed I-Premise
after I-Premise
rehabilitation I-Premise
. I-Premise

Normally O
distributed O
data O
were O
analyzed O
using O
t O
tests O
and O
random-slope/random-intercept O
mixed O
models O
. O

These O
patients O
were O
enrolled O
in O
two O
International O
Breast O
Cancer O
Study O
Group O
randomized O
clinical O
trials O
in O
operable O
breast O
cancer O
conducted O
from O
1986 O
to O
1993 O
. O

The B-Premise
duration I-Premise
of I-Premise
survival I-Premise
and I-Premise
disease-free I-Premise
survival I-Premise
at I-Premise
2 I-Premise
years I-Premise
after I-Premise
randomization I-Premise
were I-Premise
estimated I-Premise
at I-Premise
22 I-Premise
% I-Premise
and I-Premise
19 I-Premise
% I-Premise
for I-Premise
the I-Premise
control I-Premise
group I-Premise
and I-Premise
22 I-Premise
% I-Premise
and I-Premise
14 I-Premise
% I-Premise
for I-Premise
the I-Premise
GM-CSF I-Premise
group I-Premise
( I-Premise
P I-Premise
= I-Premise
NS I-Premise
) I-Premise
. I-Premise

To O
assess O
the O
QoL O
, O
a O
questionnaire O
in O
reference O
to O
the O
EORTC-QLQ-C30 O
and O
the O
QLQ-OES24 O
was O
administered O
at O
3 O
weeks O
, O
6 O
months O
and O
1 O
year O
after O
surgery O
. O

To O
assess O
the O
effectiveness O
of O
mindfulness-based O
stress O
reduction O
( O
MBSR O
) O
for O
mood O
, O
breast- O
and O
endocrine-specific O
quality O
of O
life O
, O
and O
well-being O
after O
hospital O
treatment O
in O
women O
with O
stage O
0 O
to O
III O
breast O
cancer O
. O

At B-Premise
radiotherapy I-Premise
completion I-Premise
, I-Premise
in I-Premise
G1 I-Premise
all I-Premise
QoL I-Premise
function I-Premise
scores I-Premise
improved I-Premise
proportionally I-Premise
to I-Premise
adequate I-Premise
intake I-Premise
or I-Premise
nutritional I-Premise
status I-Premise
( I-Premise
P I-Premise
< I-Premise
.05 I-Premise
) I-Premise
";" I-Premise
whereas I-Premise
in I-Premise
G2 I-Premise
only I-Premise
three I-Premise
of I-Premise
six I-Premise
function I-Premise
scores I-Premise
improved I-Premise
proportionally I-Premise
to I-Premise
protein I-Premise
intake I-Premise
( I-Premise
P I-Premise
= I-Premise
.04 I-Premise
) I-Premise
, I-Premise
and I-Premise
in I-Premise
G3 I-Premise
all I-Premise
scores I-Premise
worsened I-Premise
( I-Premise
P I-Premise
< I-Premise
.05 I-Premise
) I-Premise
. I-Premise

At B-Premise
12 I-Premise
months I-Premise
, I-Premise
exemestane I-Premise
was I-Premise
associated I-Premise
with I-Premise
fewer I-Premise
hot I-Premise
flashes I-Premise
and I-Premise
less I-Premise
vaginal I-Premise
discharge I-Premise
than I-Premise
tamoxifen I-Premise
, I-Premise
but I-Premise
with I-Premise
more I-Premise
vaginal I-Premise
dryness I-Premise
, I-Premise
bone/muscle I-Premise
aches I-Premise
, I-Premise
and I-Premise
difficulty I-Premise
sleeping I-Premise
. I-Premise

The B-Premise
overall I-Premise
response I-Premise
rate I-Premise
( I-Premise
ORR I-Premise
) I-Premise
was I-Premise
significantly I-Premise
greater I-Premise
for I-Premise
patients I-Premise
taking I-Premise
AT I-Premise
( I-Premise
59 I-Premise
% I-Premise
, I-Premise
with I-Premise
10 I-Premise
% I-Premise
complete I-Premise
response I-Premise
[ I-Premise
CR I-Premise
] I-Premise
, I-Premise
49 I-Premise
% I-Premise
partial I-Premise
response I-Premise
[ I-Premise
PR I-Premise
] I-Premise
) I-Premise
than I-Premise
for I-Premise
those I-Premise
taking I-Premise
AC I-Premise
( I-Premise
47 I-Premise
% I-Premise
, I-Premise
with I-Premise
7 I-Premise
% I-Premise
CR I-Premise
, I-Premise
39 I-Premise
% I-Premise
PR I-Premise
) I-Premise
( I-Premise
P I-Premise
=.009 I-Premise
) I-Premise
. I-Premise

Axillary B-Claim
clearance I-Claim
in I-Claim
early I-Claim
breast I-Claim
cancer I-Claim
aims I-Claim
to I-Claim
improve I-Claim
locoregional I-Claim
control I-Claim
and I-Claim
provide I-Claim
staging I-Claim
information I-Claim
but O
is O
associated O
with O
undesirable O
morbidity O
. O

All O
treatments O
were O
delivered O
on O
days O
1 O
and O
8 O
every O
3 O
weeks O
for O
a O
maximum O
of O
six O
cycles O
. O

This O
randomized O
trial O
demonstrates O
that O
ATP B-Claim
has I-Claim
beneficial I-Claim
effects I-Claim
on I-Claim
weight I-Claim
, I-Claim
muscle I-Claim
strength I-Claim
, I-Claim
and I-Claim
QOL I-Claim
in I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
NSCLC I-Claim
. I-Claim

It O
is O
recommended O
to O
provide O
pain O
management O
education O
to O
all O
cancer O
patients O
. O

No O
differences O
between O
groups O
were O
observed O
, O
with O
the O
exception O
of O
PCS O
scores O
at O
6-week O
follow-up O
: O
Patients O
in O
the O
UAE O
group O
had O
significantly O
better O
scores O
than O
did O
patients O
in O
the O
hysterectomy O
group O
( O
P O
< O
.001 O
) O
. O

Patients B-Premise
in I-Premise
the I-Premise
SNBM I-Premise
group I-Premise
gave I-Premise
lower I-Premise
ratings I-Premise
for I-Premise
arm I-Premise
swelling I-Premise
( I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
, I-Premise
symptoms I-Premise
( I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
, I-Premise
and I-Premise
dysfunctions I-Premise
( I-Premise
P I-Premise
= I-Premise
0.02 I-Premise
) I-Premise
, I-Premise
but I-Premise
not I-Premise
disabilities I-Premise
( I-Premise
P I-Premise
= I-Premise
0.5 I-Premise
) I-Premise
. I-Premise

Consented O
participants O
were O
randomized O
to O
an O
experimental O
group O
( O
EG O
) O
( O
12 O
weekly O
MMP O
sessions O
) O
or O
a O
control O
group O
( O
no O
sessions O
) O
. O

The O
majority O
of O
patients O
received O
the O
intended O
four O
cycles O
( O
GCa O
, O
64 O
% O
";" O
MIC O
, O
61 O
% O
) O
. O

A O
phase O
II O
trial O
combining O
DPPE O
and O
doxorubicin O
( O
DOX O
) O
in O
metastatic O
breast O
carcinoma O
showed O
increased O
response O
over O
that O
expected O
with O
DOX O
. O

To O
test O
the O
equivalence O
of O
three O
versus O
four O
cycles O
of O
bleomycin O
, O
etoposide O
, O
and O
cisplatin O
( O
BEP O
) O
and O
of O
the O
5-day O
schedule O
versus O
3 O
days O
per O
cycle O
in O
good-prognosis O
germ O
cell O
cancer O
. O

Malignant B-Claim
pleural I-Claim
effusion I-Claim
( I-Claim
MPE I-Claim
) I-Claim
is I-Claim
a I-Claim
common I-Claim
complication I-Claim
of I-Claim
advanced I-Claim
non-small I-Claim
cell I-Claim
lung I-Claim
cancer I-Claim
( I-Claim
NSCLC I-Claim
) I-Claim
. I-Claim

No O
significant O
difference O
in O
outcome O
was O
found O
between O
the O
patients O
with O
and O
without O
baseline O
FACT-H O
& O
amp O
";" O
N O
data O
( O
p O
= O
0.58 O
) O
. O

203 O
women O
entered O
the O
study O
";" O
177 O
completed O
the O
six O
month O
follow-up O
. O

Time B-Premise
to I-Premise
5 I-Premise
% I-Premise
deterioration I-Premise
of I-Premise
global I-Premise
health I-Premise
status I-Premise
( I-Premise
primary I-Premise
end I-Premise
point I-Premise
) I-Premise
significantly I-Premise
favored I-Premise
DCF I-Premise
over I-Premise
CF I-Premise
( I-Premise
log-rank I-Premise
test I-Premise
, I-Premise
P I-Premise
= I-Premise
.01 I-Premise
) I-Premise
. I-Premise

Although O
initial O
pre-trial O
interviews O
revealed O
concerns O
among O
health-care O
professionals O
and O
some O
patients O
regarding O
community O
treatment O
, O
opinions O
were O
largely O
more O
favourable O
in O
post-trial O
interviews O
. O

Subjects O
( O
N O
= O
27 O
) O
were O
patients O
admitted O
for O
some O
type O
of O
surgical O
procedure O
of O
the O
brain O
. O

Irinotecan B-Claim
schedules I-Claim
of I-Claim
weekly I-Claim
and I-Claim
of I-Claim
once I-Claim
every I-Claim
3 I-Claim
weeks I-Claim
demonstrated I-Claim
similar I-Claim
efficacy I-Claim
and I-Claim
quality I-Claim
of I-Claim
life I-Claim
in I-Claim
patients I-Claim
with I-Claim
FU-refractory I-Claim
, I-Claim
metastatic I-Claim
colorectal I-Claim
cancer I-Claim
. I-Claim

Of O
these O
70 O
patients O
, O
46 O
underwent O
pretreatment O
FLIC O
and O
49 O
underwent O
pretreatment O
FACT-L O
. O

Intrusive B-Premise
thoughts I-Premise
were I-Premise
associated I-Premise
with I-Premise
higher I-Premise
levels I-Premise
of I-Premise
all I-Premise
symptoms I-Premise
at I-Premise
baseline I-Premise
and I-Premise
at I-Premise
the I-Premise
12-month I-Premise
assessment I-Premise
. I-Premise

QOL O
was O
assessed O
over O
a O
1-year O
follow-up O
period O
, O
using O
the O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
Quality O
of O
Life O
Questionnaire O
C-30 O
. O

A O
randomised O
controlled O
trial O
( O
RCT O
) O
demonstrated O
that O
cognitive O
behaviour O
therapy O
( O
CBT O
) O
for O
fatigue O
during O
curative O
cancer O
treatment O
was O
effective O
shortly O
after O
cancer O
treatment O
. O

Complicated B-Premise
neutropenia I-Premise
was I-Premise
more I-Premise
frequent I-Premise
with I-Premise
DCF I-Premise
than I-Premise
CF I-Premise
( I-Premise
29 I-Premise
% I-Premise
v I-Premise
12 I-Premise
% I-Premise
) I-Premise
. I-Premise

Women B-Premise
with I-Premise
advanced I-Premise
breast I-Premise
cancer I-Premise
randomized I-Premise
to I-Premise
the I-Premise
seated I-Premise
exercise I-Premise
intervention I-Premise
had I-Premise
a I-Premise
slower I-Premise
decline I-Premise
in I-Premise
total I-Premise
and I-Premise
physical I-Premise
well-being I-Premise
and I-Premise
less I-Premise
increase I-Premise
in I-Premise
fatigue I-Premise
scores I-Premise
starting I-Premise
with I-Premise
the I-Premise
third I-Premise
cycle I-Premise
of I-Premise
chemotherapy I-Premise
. I-Premise

At B-Premise
enrollment I-Premise
, I-Premise
symptoms I-Premise
, I-Premise
including I-Premise
muscle I-Premise
stiffness I-Premise
, I-Premise
breast I-Premise
sensitivity I-Premise
, I-Premise
aches I-Premise
and I-Premise
pains I-Premise
, I-Premise
tendency I-Premise
to I-Premise
take I-Premise
naps I-Premise
, I-Premise
and I-Premise
difficulty I-Premise
concentrating I-Premise
, I-Premise
were I-Premise
common I-Premise
among I-Premise
patients I-Premise
in I-Premise
all I-Premise
groups I-Premise
and I-Premise
were I-Premise
statistically I-Premise
significantly I-Premise
associated I-Premise
with I-Premise
poor I-Premise
physical I-Premise
functioning I-Premise
and I-Premise
emotional I-Premise
well-being I-Premise
. I-Premise

For B-Premise
willingness-to-pay I-Premise
between I-Premise
$ I-Premise
5000 I-Premise
and I-Premise
$ I-Premise
40 I-Premise
0 I-Premise
per I-Premise
quality-adjusted I-Premise
life I-Premise
year I-Premise
, I-Premise
the I-Premise
single-fraction I-Premise
schedule I-Premise
was I-Premise
statistically I-Premise
significantly I-Premise
more I-Premise
cost-effective I-Premise
than I-Premise
the I-Premise
multiple-fraction I-Premise
schedule I-Premise
( I-Premise
P I-Premise
< I-Premise
or I-Premise
=.05 I-Premise
) I-Premise
. I-Premise

Fifty-nine B-Premise
percent I-Premise
of I-Premise
those I-Premise
initially I-Premise
receiving I-Premise
duloxetine I-Premise
vs I-Premise
38 I-Premise
% I-Premise
of I-Premise
those I-Premise
initially I-Premise
receiving I-Premise
placebo I-Premise
reported I-Premise
decreased I-Premise
pain I-Premise
of I-Premise
any I-Premise
amount I-Premise
. I-Premise

Eighteen B-Premise
patients I-Premise
receiving I-Premise
IFN5 I-Premise
and I-Premise
4 I-Premise
patients I-Premise
receiving I-Premise
IFN1 I-Premise
had I-Premise
dose I-Premise
reductions I-Premise
( I-Premise
P I-Premise
= I-Premise
.002 I-Premise
) I-Premise
. I-Premise

A O
total O
of O
402 O
eligible O
patients O
were O
registered O
to O
step O
1 O
, O
and O
223 O
eligible O
patients O
were O
registered O
to O
step O
2 O
( O
observation O
, O
n O
= O
111 O
";" O
topotecan O
, O
n O
= O
112 O
) O
. O

Participants B-Premise
in I-Premise
the I-Premise
Internet I-Premise
group I-Premise
showed I-Premise
significant I-Premise
improvements I-Premise
at I-Premise
post-assessment I-Premise
compared I-Premise
with I-Premise
those I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
in I-Premise
overall I-Premise
insomnia I-Premise
severity I-Premise
( I-Premise
F I-Premise
( I-Premise
1,26 I-Premise
) I-Premise
= I-Premise
22.8 I-Premise
";" I-Premise
p I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
, I-Premise
sleep I-Premise
efficiency I-Premise
( I-Premise
F I-Premise
( I-Premise
1,24 I-Premise
) I-Premise
= I-Premise
11.45 I-Premise
";" I-Premise
P I-Premise
= I-Premise
0.002 I-Premise
) I-Premise
, I-Premise
sleep I-Premise
onset I-Premise
latency I-Premise
( I-Premise
F I-Premise
( I-Premise
1,24 I-Premise
) I-Premise
= I-Premise
5.18 I-Premise
";" I-Premise
P I-Premise
= I-Premise
0.03 I-Premise
) I-Premise
, I-Premise
soundness I-Premise
of I-Premise
sleep I-Premise
( I-Premise
F I-Premise
( I-Premise
1,24 I-Premise
) I-Premise
= I-Premise
9.34 I-Premise
";" I-Premise
P I-Premise
= I-Premise
0.005 I-Premise
) I-Premise
, I-Premise
restored I-Premise
feeling I-Premise
upon I-Premise
awakening I-Premise
( I-Premise
F I-Premise
( I-Premise
1,24 I-Premise
) I-Premise
= I-Premise
11.95 I-Premise
";" I-Premise
P I-Premise
= I-Premise
0.002 I-Premise
) I-Premise
, I-Premise
and I-Premise
general I-Premise
fatigue I-Premise
( I-Premise
F I-Premise
( I-Premise
1,26 I-Premise
) I-Premise
= I-Premise
13.88 I-Premise
";" I-Premise
P I-Premise
= I-Premise
0.001 I-Premise
) I-Premise
. I-Premise

( O
600 O
mg/m O
( O
2 O
) O
day O
1-28 O
of O
a O
56-day O
cycle O
) O
for O
a O
maximum O
of O
12 O
cycles O
( O
i.v O
. O
) O

The O
sample O
of O
patients O
( O
n O
= O
709 O
) O
newly O
admitted O
to O
hospice O
home O
care O
in O
2 O
hospices O
had O
designated O
family O
caregivers O
. O

Small B-Claim
sample I-Claim
size I-Claim
precludes I-Claim
definitive I-Claim
answers I-Claim
, I-Claim
but B-Claim
results I-Claim
from I-Claim
this I-Claim
preliminary I-Claim
trial I-Claim
suggest I-Claim
that I-Claim
homeopathy I-Claim
may I-Claim
be I-Claim
of I-Claim
value I-Claim
in I-Claim
the I-Claim
treatment I-Claim
of I-Claim
menopausal I-Claim
symptoms I-Claim
and I-Claim
improving I-Claim
quality I-Claim
of I-Claim
life I-Claim
, I-Claim
especially I-Claim
in I-Claim
those I-Claim
women I-Claim
not I-Claim
on I-Claim
tamoxifen I-Claim
. I-Claim

Comparing B-Claim
the I-Claim
results I-Claim
2 I-Claim
and I-Claim
3 I-Claim
years I-Claim
after I-Claim
radiotherapy I-Claim
, I-Claim
the I-Claim
symptoms I-Claim
of I-Claim
rectal I-Claim
bleeding I-Claim
had I-Claim
improved I-Claim
, I-Claim
erectile I-Claim
function I-Claim
had I-Claim
decreased I-Claim
, I-Claim
and I-Claim
urinary I-Claim
urge I-Claim
incontinence I-Claim
had I-Claim
increased I-Claim
. I-Claim

on O
day O
1 O
, O
followed O
on O
day O
2 O
by O
LFA O
, O
250 O
mg/m2 O
i.v O
. O

This B-Claim
effect I-Claim
is I-Claim
an I-Claim
important I-Claim
clinically I-Claim
meaningful I-Claim
reduction I-Claim
from I-Claim
baseline I-Claim
in I-Claim
the I-Claim
cisplatin/raltitrexed I-Claim
arm I-Claim
. I-Claim

The O
efficacy O
and O
safety O
of O
letrozole O
therapy O
beyond O
5 O
years O
is O
being O
assessed O
in O
a O
re-randomization O
study O
, O
following O
the O
emergence O
of O
new O
data O
suggesting O
that O
clinical O
benefit O
correlates O
with O
the O
duration O
of O
letrozole O
. O

Eligible O
patients O
were O
70 O
years O
of O
age O
or O
older O
, O
had O
stage O
IV O
or O
IIIB O
NSCLC O
that O
was O
ineligible O
for O
radiotherapy O
, O
and O
had O
a O
performance O
status O
of O
0-2 O
( O
a O
status O
of O
fully O
active O
to O
a O
status O
of O
capable O
of O
all O
self-care O
but O
unable O
to O
work O
) O
. O

No B-Premise
significant I-Premise
differences I-Premise
were I-Premise
seen I-Premise
in I-Premise
favour I-Premise
of I-Premise
the I-Premise
supportive I-Premise
care I-Premise
group I-Premise
, I-Premise
except B-Premise
for I-Premise
hair I-Premise
loss I-Premise
. I-Premise

In O
the O
comparison O
of O
responders O
versus O
patients O
with O
both O
SD O
( O
6m O
) O
and O
PD O
, O
responders B-Premise
indicated I-Premise
better I-Premise
physical I-Premise
well-being I-Premise
( I-Premise
P I-Premise
= I-Premise
. I-Premise
4 I-Premise
) I-Premise
and I-Premise
mood I-Premise
( I-Premise
P I-Premise
=.02 I-Premise
) I-Premise
at I-Premise
month I-Premise
3 I-Premise
. I-Premise

438 O
of O
439 O
men O
assigned O
endocrine O
treatment O
and O
434 O
of O
436 O
assigned O
endocrine O
plus O
radiotherapy O
completed O
at O
least O
one O
questionnaire O
. O

The O
aim O
of O
this O
study O
was O
to O
compare O
the O
analgesic O
and O
adverse O
effects O
, O
doses O
, O
as O
well O
as O
cost O
of O
opioid O
drugs O
, O
supportive O
drug O
therapy O
and O
other O
analgesic O
drugs O
in O
patients O
treated O
with O
oral O
sustained-release O
morphine O
, O
transdermal O
fentanyl O
, O
and O
oral O
methadone O
. O

Secondary O
outcome O
measures O
were O
recurrence O
rates O
, O
functional O
status O
, O
treatment-related O
morbidity O
and O
cosmesis O
. O

Mean B-Premise
physical I-Premise
function I-Premise
at I-Premise
12 I-Premise
months I-Premise
was I-Premise
66 I-Premise
points I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
62·9-70·0 I-Premise
) I-Premise
in I-Premise
the I-Premise
90 I-Premise
mg I-Premise
group I-Premise
and I-Premise
68 I-Premise
points I-Premise
( I-Premise
64·6-71·4 I-Premise
) I-Premise
in I-Premise
the I-Premise
30 I-Premise
mg I-Premise
group I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
of I-Premise
difference I-Premise
-6·6 I-Premise
to I-Premise
3·3 I-Premise
";" I-Premise
p=0·52 I-Premise
) I-Premise
. I-Premise

QOL B-Claim
was I-Claim
similar I-Claim
for I-Claim
both I-Claim
arms I-Claim
. I-Claim

Median O
age O
was O
76 O
years O
( O
range O
, O
70 O
years O
to O
86 O
years O
) O
. O

We O
obtained O
quality-of-life O
information O
from O
872 O
( O
99 O
% O
) O
of O
875 O
eligible O
men O
with O
locally O
advanced O
prostate O
cancer O
( O
T3 O
";" O
78 O
% O
) O
who O
were O
randomly O
assigned O
, O
between O
1996 O
and O
2002 O
, O
to O
3 O
months O
of O
total O
androgen O
blockade O
followed O
by O
continuous O
endocrine O
treatment O
( O
439 O
patients O
) O
or O
the O
same O
hormonal O
treatment O
with O
radiotherapy O
3 O
months O
after O
randomisation O
( O
436 O
patients O
) O
. O

treosulfan O
for O
the O
treatment O
of O
relapsed O
ovarian O
carcinoma O
, O
women O
aged O
65 O
years O
or O
older O
were O
included O
in O
this O
prospective O
multicenter O
study O
. O

To O
carry O
out O
a O
preliminary O
trial O
evaluating O
the O
effectiveness O
of O
two O
types O
of O
homeopathy O
for O
the O
treatment O
of O
menopausal O
symptoms O
in O
breast O
cancer O
survivors O
. O

SNBM B-Claim
was I-Claim
successfully I-Claim
undertaken I-Claim
in I-Claim
a I-Claim
wide I-Claim
range I-Claim
of I-Claim
surgical I-Claim
centers I-Claim
and I-Claim
caused I-Claim
significantly I-Claim
less I-Claim
morbidity I-Claim
than I-Claim
RAC I-Claim
. I-Claim

Treatment B-Claim
with I-Claim
PB+G I-Claim
increased I-Claim
the I-Claim
incidence I-Claim
of I-Claim
severe I-Claim
neutropenia I-Claim
and I-Claim
dyspnea I-Claim
, I-Claim
although B-Claim
the I-Claim
regimen I-Claim
generally I-Claim
was I-Claim
well I-Claim
tolerated I-Claim
. I-Claim

The O
Wilcoxon O
rank O
sum O
test O
was O
used O
to O
compare O
summary O
scores O
between O
the O
two O
interventions O
. O

The O
primary O
endpoint O
was O
overall O
survival O
, O
and O
secondary O
endpoints O
were O
progression-free O
survival O
, O
response O
rate O
, O
toxicity O
, O
and O
quality O
of O
life O
. O

One O
hundred O
two O
patients O
with O
resected O
PPC O
consented O
to O
participate O
in O
this O
study O
and O
were O
randomized O
to O
either O
an O
intervention O
group O
( O
IG O
) O
or O
a O
usual O
care O
group O
( O
UCG O
) O
. O

Median B-Premise
time I-Premise
to I-Premise
progression I-Premise
was I-Premise
6.9 I-Premise
( I-Premise
4.6-10.1 I-Premise
) I-Premise
and I-Premise
9.2 I-Premise
( I-Premise
7.9-11.5 I-Premise
) I-Premise
months I-Premise
and I-Premise
median I-Premise
overall I-Premise
survival I-Premise
was I-Premise
17.4 I-Premise
( I-Premise
12.6-23.0+ I-Premise
) I-Premise
and I-Premise
24.7 I-Premise
( I-Premise
16.3-26.4+ I-Premise
) I-Premise
months I-Premise
. I-Premise

Both B-Premise
EBRT I-Premise
and I-Premise
cryoablation I-Premise
participants I-Premise
reported I-Premise
decreases I-Premise
in I-Premise
sexual I-Premise
function I-Premise
at I-Premise
3 I-Premise
months I-Premise
with I-Premise
the I-Premise
cryoablation I-Premise
patients I-Premise
reporting I-Premise
poorer I-Premise
functioning I-Premise
( I-Premise
mean I-Premise
cryoablation=7.2 I-Premise
: I-Premise
mean I-Premise
EBRT=32.9 I-Premise
";" I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
. I-Premise

The B-Claim
TOM I-Claim
+ I-Claim
LFA I-Claim
5-FU I-Claim
regimen I-Claim
showed I-Claim
a I-Claim
RR I-Claim
and I-Claim
a I-Claim
toxicity I-Claim
profile I-Claim
very I-Claim
close I-Claim
to I-Claim
the I-Claim
MTX I-Claim
+ I-Claim
LFA I-Claim
5-FU I-Claim
combination I-Claim
, I-Claim
and I-Claim
does I-Claim
not I-Claim
deserve I-Claim
further I-Claim
evaluation I-Claim
in I-Claim
advanced I-Claim
colorectal I-Claim
cancer I-Claim
patients I-Claim
. I-Claim

Attrition B-Premise
rates I-Premise
did I-Premise
not I-Premise
vary I-Premise
significantly I-Premise
between I-Premise
study I-Premise
arms I-Premise
. I-Premise

However O
, O
it O
is O
unclear O
whether O
or O
not O
this O
administration O
method O
can O
improve O
the O
patients O
' O
quality O
of O
life O
( O
QOL O
) O
. O

All O
patients O
were O
chemotherapy-naïve O
and O
had O
an O
ECOG O
performance O
status O
( O
PS O
) O
of O
0-1 O
. O

cancer O
survivors O
with O
different O
diagnoses O
, O
and O
cancer-related O
physical O
and O
psychosocial O
problems O
. O

The B-Claim
small I-Claim
sample I-Claim
size I-Claim
may I-Claim
have I-Claim
limited I-Claim
our I-Claim
ability I-Claim
to I-Claim
detect I-Claim
significant I-Claim
differences I-Claim
beyond I-Claim
6 I-Claim
months I-Claim
of I-Claim
observation I-Claim
as I-Claim
well I-Claim
as I-Claim
additional I-Claim
significant I-Claim
differences I-Claim
in I-Claim
our I-Claim
study I-Claim
. I-Claim

Venlafaxine O
( O
Effexor O
) O
, O
the O
therapy O
of O
choice O
for O
these O
symptoms O
, O
has O
numerous O
adverse O
effects O
. O

The B-Claim
analgesic I-Claim
effects I-Claim
of I-Claim
amitriptyline I-Claim
were I-Claim
slight I-Claim
and I-Claim
associated I-Claim
with I-Claim
adverse I-Claim
effects I-Claim
. I-Claim

To O
investigate O
the O
impact O
of O
dietary O
counseling O
or O
nutritional O
supplements O
on O
outcomes O
in O
cancer O
patients O
: O
nutritional O
, O
morbidity O
, O
and O
quality O
of O
life O
( O
QoL O
) O
during O
and O
3 O
months O
after O
radiotherapy O
. O

This O
study O
compares O
the O
clinical O
effectiveness O
and O
cost-effectiveness O
of O
self-expanding O
metal O
stents O
( O
SEMSs O
) O
with O
other O
palliative O
therapies O
to O
aid O
clinicians O
in O
making O
an O
evidence-based O
treatment O
choice O
. O

No B-Premise
significant I-Premise
differences I-Premise
were I-Premise
noted I-Premise
in I-Premise
the I-Premise
distress I-Premise
levels I-Premise
before I-Premise
and I-Premise
after I-Premise
completion I-Premise
of I-Premise
the I-Premise
study I-Premise
in I-Premise
the I-Premise
three I-Premise
groups I-Premise
. I-Premise

Patients O
were O
randomized O
to O
receive O
21-day O
cycles O
of O
oral O
capecitabine O
1250 O
mg/m2 O
twice O
daily O
, O
on O
Days O
1-14 O
, O
plus O
docetaxel O
75 O
mg/m2 O
Day O
1 O
( O
n O
= O
255 O
) O
, O
or O
docetaxel O
100 O
mg/m2 O
on O
Day O
1 O
( O
n O
= O
256 O
) O
. O

Repeated O
measures O
MANCOVA O
was O
used O
to O
evaluate O
outcomes O
. O

AT B-Claim
significantly I-Claim
improves I-Claim
TTP I-Claim
and I-Claim
ORR I-Claim
compared I-Claim
with I-Claim
AC I-Claim
in I-Claim
patients I-Claim
with I-Claim
MBC I-Claim
, I-Claim
but B-Claim
there I-Claim
is I-Claim
no I-Claim
difference I-Claim
in I-Claim
OS I-Claim
. I-Claim

There B-Premise
was I-Premise
a I-Premise
high I-Premise
rate I-Premise
of I-Premise
grade I-Premise
3/4 I-Premise
neutropenia I-Premise
( I-Premise
97 I-Premise
% I-Premise
) I-Premise
but I-Premise
not I-Premise
neutropenic I-Premise
fever I-Premise
( I-Premise
12 I-Premise
% I-Premise
) I-Premise
during I-Premise
neoadjuvant I-Premise
chemotherapy I-Premise
. I-Premise

In B-Claim
patients I-Claim
with I-Claim
polycystic I-Claim
liver I-Claim
, I-Claim
6 I-Claim
months I-Claim
of I-Claim
treatment I-Claim
with I-Claim
lanreotide I-Claim
reduces I-Claim
liver I-Claim
volume I-Claim
. I-Claim

When B-Premise
combined I-Premise
hormone I-Premise
therapy I-Premise
( I-Premise
n=2196 I-Premise
) I-Premise
was I-Premise
compared I-Premise
with I-Premise
placebo I-Premise
( I-Premise
n=2189 I-Premise
) I-Premise
, I-Premise
there I-Premise
was I-Premise
a I-Premise
significant I-Premise
increase I-Premise
in I-Premise
the I-Premise
number I-Premise
of I-Premise
major I-Premise
cardiovascular I-Premise
events I-Premise
( I-Premise
7 I-Premise
v I-Premise
0 I-Premise
, I-Premise
P=0.016 I-Premise
) I-Premise
and I-Premise
venous I-Premise
thromboembolisms I-Premise
( I-Premise
22 I-Premise
v I-Premise
3 I-Premise
, I-Premise
hazard I-Premise
ratio I-Premise
7.36 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
2.20 I-Premise
to I-Premise
24.60 I-Premise
) I-Premise
) I-Premise
. I-Premise

Two O
promising O
approaches O
to O
address O
this O
include O
dance/movement O
therapy O
and O
mindfulness O
. O

Clinicians O
working O
with O
patients O
who O
have O
advanced O
cancer O
should O
consider O
IMCP O
as O
an O
approach O
to O
enhance O
quality O
of O
life O
and O
spiritual O
well-being O
. O

QOL O
was O
assessed O
by O
European O
Organisation O
for O
Research O
and O
Treatment O
of O
Cancer O
QLQ-C30 O
and O
the O
lung O
cancer O
module O
QLQ-LC13 O
. O

Patients O
were O
evaluated O
on O
five O
occasions O
over O
the O
experimental O
period O
. O

We O
performed O
a O
randomized O
, O
double-blind O
, O
28-day O
trial O
of O
melatonin O
20 O
mg O
versus O
placebo O
in O
patients O
with O
advanced O
lung O
or O
GI O
cancer O
, O
appetite O
scores O
≥ O
4 O
on O
a O
0 O
to O
10 O
scale O
( O
10 O
= O
worst O
appetite O
) O
, O
and O
history O
of O
weight O
loss O
≥ O
5 O
% O
. O

194 O
women O
representative O
of O
the O
breast O
cancer O
population O
were O
randomised O
to O
the O
FtF O
( O
n O
= O
67 O
) O
, O
Tel O
( O
n O
= O
67 O
) O
and O
UC O
( O
n O
= O
60 O
) O
groups O
. O

The O
primary O
outcome O
was O
the O
difference O
in O
the O
change O
in O
Functional O
Assessment O
of O
Cancer O
Therapy-Anemia O
scores O
between O
baseline O
and O
12 O
weeks O
. O

The B-Premise
successful I-Premise
ablation I-Premise
rate I-Premise
was I-Premise
91.0 I-Premise
% I-Premise
in I-Premise
T4-WD I-Premise
Group I-Premise
, I-Premise
91.7 I-Premise
% I-Premise
in I-Premise
T3-WD I-Premise
Group I-Premise
, I-Premise
and I-Premise
91.3 I-Premise
% I-Premise
in I-Premise
rhTSH I-Premise
Group I-Premise
, I-Premise
without I-Premise
significant I-Premise
between-preparation I-Premise
differences I-Premise
( I-Premise
p I-Premise
= I-Premise
0.2061 I-Premise
) I-Premise
. I-Premise

During O
the O
first O
year O
of O
treatment O
, O
HRQOL O
and O
symptoms O
of O
depression O
were O
analyzed O
using O
the O
Functional O
Assessment O
of O
Cancer O
Therapy-Breast O
( O
FACT-B O
) O
and O
its O
Endocrine O
Symptom O
Subscale O
( O
ES O
) O
, O
and O
the O
Center O
for O
Epidemiologic O
Studies O
Depression O
Scale O
( O
CES-D O
) O
, O
respectively O
. O

These O
patients O
were O
assigned O
to O
the O
two O
arms O
to O
assess O
the O
value O
of O
low-dose O
CDDP O
when O
added O
to O
a O
continuous O
intravenous O
infusion O
of O
5-FU O
at O
a O
dose O
of O
300 O
mg/m O
( O
2 O
) O
/24 O
hrs O
in O
a O
one-week O
cycle O
consisting O
of O
5 O
days O
of O
treatment O
and O
2 O
days O
of O
rest O
for O
at O
least O
12 O
weeks O
. O

Relapse B-Claim
after I-Claim
completing I-Claim
adjuvant I-Claim
tamoxifen I-Claim
therapy I-Claim
is I-Claim
a I-Claim
persistent I-Claim
threat I-Claim
for I-Claim
women I-Claim
with I-Claim
hormone-responsive I-Claim
breast I-Claim
cancer I-Claim
. I-Claim

A O
high O
percentage O
of O
patients O
with O
newly O
diagnosed O
early O
stage O
breast O
cancer O
were O
found O
to O
have O
depressive O
symptoms O
prior O
to O
the O
initiation O
of O
adjuvant O
therapy O
. O

However O
, O
there O
is O
a O
wide O
heterogeneity O
in O
the O
clinical O
impact O
of O
hypothyroidism O
. O

In O
a O
randomized O
Phase O
II O
trial O
, O
the O
authors O
tested O
the O
hypothesis O
that O
twice-daily O
low-dose O
IFN O
is O
more O
effective O
than O
daily O
intermediate-dose O
IFN O
in O
patients O
with O
metastatic O
renal O
cell O
cancer O
( O
MRCC O
) O
. O

We O
randomly O
assigned O
patients O
who O
had O
completed O
primary O
cancer O
treatment O
within O
the O
past O
24 O
months O
in O
any O
of O
four O
Korean O
hospitals O
and O
had O
reported O
moderate O
to O
severe O
fatigue O
for O
at O
least O
1 O
week O
to O
participate O
in O
a O
12-week O
, O
Internet-based O
, O
individually O
tailored O
CRF O
education O
program O
or O
to O
receive O
routine O
care O
. O

QOL B-Premise
analyses I-Premise
favored I-Premise
Arm I-Premise
A. I-Premise
SGN-15 B-Claim
plus I-Claim
docetaxel I-Claim
is I-Claim
a I-Claim
well-tolerated I-Claim
and I-Claim
active I-Claim
second I-Claim
and I-Claim
third I-Claim
line I-Claim
treatment I-Claim
for I-Claim
NSCLC I-Claim
patients I-Claim
. O

The O
aim O
of O
this O
study O
was O
to O
investigate O
whether O
specialized O
supportive O
enteral O
and O
parenteral O
feeding O
have O
superior O
effects O
compared O
to O
oral O
nutrition O
on O
recovery O
during O
long-term O
postoperative O
treatment O
of O
cancer O
patients O
with O
preoperative O
weight O
loss O
and O
reduced O
maximum O
exercise O
capacity O
. O

Patients O
with O
advanced O
NSCLC O
with O
no O
evidence O
of O
progression O
after O
four O
cycles O
of O
chemotherapy O
were O
randomized O
to O
receive O
erlotinib O
150 O
mg/day O
or O
placebo O
, O
until O
progressive O
disease O
or O
limiting O
toxicity O
. O

This O
was O
a O
randomized O
, O
parallel-arm O
, O
active-controlled O
, O
open-label O
, O
multicentre O
trial O
on O
182 O
patients O
treated O
with O
either O
monthly O
degarelix O
( O
240/80 O
mg O
) O
or O
goserelin O
( O
3.6 O
mg O
) O
for O
12 O
weeks O
. O

We O
compared O
the O
combination O
of O
docetaxel-carboplatin O
with O
the O
combination O
of O
paclitaxel-carboplatin O
as O
first-line O
chemotherapy O
for O
stage O
Ic-IV O
epithelial O
ovarian O
or O
primary O
peritoneal O
cancer O
. O

Patients O
in O
the O
three O
groups O
did O
not O
differ O
significantly O
in O
baseline O
characteristics O
or O
tumor O
, O
node O
and O
metastasis O
( O
TNM O
) O
staging O
. O

Ninety-four O
patients O
were O
evaluable O
for O
efficacy O
and O
safety O
. O

Data O
were O
analysed O
up O
to O
6 O
months O
. O

The B-Premise
quality I-Premise
of I-Premise
life I-Premise
was I-Premise
almost I-Premise
the I-Premise
same I-Premise
between I-Premise
the I-Premise
arms I-Premise
. O

Patients B-Premise
in I-Premise
the I-Premise
standard I-Premise
treatment I-Premise
group I-Premise
showed I-Premise
a I-Premise
greater I-Premise
decline I-Premise
in I-Premise
Trial I-Premise
Outcome I-Premise
Index I-Premise
( I-Premise
TOI I-Premise
) I-Premise
scores I-Premise
( I-Premise
physical I-Premise
well-being I-Premise
, I-Premise
functional I-Premise
well-being I-Premise
and I-Premise
breast I-Premise
cancer I-Premise
concerns I-Premise
subscales I-Premise
in I-Premise
FACT-B+4 I-Premise
) I-Premise
and I-Premise
recovered I-Premise
more I-Premise
slowly I-Premise
than I-Premise
patients I-Premise
in I-Premise
the I-Premise
SNB I-Premise
group I-Premise
( I-Premise
p I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
. I-Premise

A O
total O
of O
513 O
patients O
were O
enrolled O
when O
a O
planned O
interim O
analysis O
recommended O
early O
closure O
for O
futility O
. O

In B-Premise
pamidronate I-Premise
LD I-Premise
patients I-Premise
, I-Premise
event-rates I-Premise
decreased I-Premise
by I-Premise
15 I-Premise
% I-Premise
to I-Premise
45 I-Premise
% I-Premise
( I-Premise
P I-Premise
< I-Premise
or I-Premise
= I-Premise
.04 I-Premise
) I-Premise
. I-Premise

Immediate B-Premise
partial I-Premise
lung I-Premise
expansion I-Premise
was I-Premise
a I-Premise
frequent I-Premise
finding I-Premise
and I-Premise
was I-Premise
more I-Premise
frequent I-Premise
after I-Premise
TS I-Premise
. I-Premise

Additional B-Claim
studies I-Claim
should I-Claim
be I-Claim
done I-Claim
in I-Claim
this I-Claim
area I-Claim
to I-Claim
determine I-Claim
the I-Claim
optimum I-Claim
training I-Claim
program I-Claim
. I-Claim

The O
primary O
endpoint O
was O
the O
proportion O
of O
patients O
without O
progression O
at O
2 O
years O
. O

carboplatin O
300 O
mg/m2 O
on O
day O
1 O
and O
etoposide O
120 O
mg/m2 O
orally O
on O
days O
1-5 O
every O
4 O
weeks O
for O
a O
maximum O
of O
eight O
courses O
. O

QUARTZ O
was O
threatened O
with O
both O
loss O
of O
funding O
and O
early O
closure O
due O
to O
poor O
accrual O
. O

We B-Claim
propose I-Claim
that I-Claim
VEGF I-Claim
expression I-Claim
levels I-Claim
in I-Claim
MPE I-Claim
could I-Claim
serve I-Claim
as I-Claim
a I-Claim
prognostic I-Claim
marker I-Claim
for I-Claim
bevacizumab I-Claim
therapy I-Claim
. I-Claim

QoL O
was O
assessed O
using O
the O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
QLQ-C30 O
questionnaire O
. O

The O
benefits O
of O
the O
intervention O
were O
evaluated O
using O
the O
Zung O
Self-rating O
Depression O
Scale O
( O
SDS O
) O
to O
measure O
depression O
, O
the O
Self-rating O
Anxiety O
Scale O
( O
SAS O
) O
to O
assess O
anxiety O
, O
and O
the O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
Quality O
of O
Life O
Questionnaire-Core O
30 O
( O
EORTC O
QLQ-C30 O
) O
to O
survey O
health-related O
QOL O
. O

Patients O
with O
cancer O
are O
characterized O
by O
a O
profound O
impairment O
of O
glucose O
utilization O
, O
with O
lipids O
being O
the O
preferred O
metabolic O
fuel O
. O

In B-Claim
patients I-Claim
with I-Claim
advanced I-Claim
breast I-Claim
cancer I-Claim
who I-Claim
develop I-Claim
disease I-Claim
progression I-Claim
after I-Claim
treatment I-Claim
with I-Claim
nonsteroidal I-Claim
aromatase I-Claim
inhibitors I-Claim
, I-Claim
EVE I-Claim
+ I-Claim
EXE I-Claim
was I-Claim
associated I-Claim
with I-Claim
a I-Claim
longer I-Claim
TDD I-Claim
in I-Claim
global I-Claim
HRQOL I-Claim
versus I-Claim
PBO I-Claim
+ I-Claim
EXE I-Claim
. I-Claim

Prespecified O
outcomes O
were O
three O
genitourinary O
symptoms O
( O
bowel O
function O
tenderness O
, O
frequent O
urination O
, O
and O
erectile O
dysfunction O
[ O
ED O
] O
) O
and O
measures O
of O
physical O
and O
emotional O
function O
. O

Major B-Premise
toxicity I-Premise
was I-Premise
similar I-Premise
across I-Premise
all I-Premise
three I-Premise
groups I-Premise
. I-Premise

Median B-Premise
survival I-Premise
from I-Premise
randomisation I-Premise
was I-Premise
25·7 I-Premise
months I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
23·0-27·9 I-Premise
) I-Premise
for I-Premise
patients I-Premise
on I-Premise
early I-Premise
treatment I-Premise
and I-Premise
27·1 I-Premise
months I-Premise
( I-Premise
22·8-30·9 I-Premise
) I-Premise
for I-Premise
those I-Premise
on I-Premise
delayed I-Premise
treatment I-Premise
. I-Premise

Most B-Premise
frequent I-Premise
non-hematological I-Premise
toxicities I-Premise
were I-Premise
nausea I-Premise
( I-Premise
76 I-Premise
% I-Premise
) I-Premise
, I-Premise
constipation I-Premise
( I-Premise
68 I-Premise
% I-Premise
) I-Premise
, I-Premise
and I-Premise
fatigue I-Premise
( I-Premise
64 I-Premise
% I-Premise
) I-Premise
. I-Premise

Seated B-Claim
exercise I-Claim
may I-Claim
be I-Claim
a I-Claim
feasible I-Claim
exercise I-Claim
program I-Claim
for I-Claim
women I-Claim
with I-Claim
advanced I-Claim
cancer I-Claim
for I-Claim
controlling I-Claim
fatigue I-Claim
and I-Claim
improving I-Claim
physical I-Claim
well-being I-Claim
. I-Claim

Survival B-Premise
without I-Premise
disease I-Premise
progression I-Premise
or I-Premise
deterioration I-Premise
in I-Premise
global I-Premise
health I-Premise
status I-Premise
was I-Premise
longer I-Premise
in I-Premise
patients I-Premise
allocated I-Premise
to I-Premise
oxaliplatin I-Premise
treatment I-Premise
( I-Premise
P I-Premise
=.004 I-Premise
) I-Premise
. I-Premise

However O
, O
because O
of O
toxicity O
associated O
with O
long-term O
bisphosphonate O
treatment O
, O
establishing O
the O
lowest O
effective O
dose O
is O
important O
. O

There B-Premise
were I-Premise
significant I-Premise
( I-Premise
p I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
interaction I-Premise
effects I-Premise
on I-Premise
QoL I-Premise
, I-Premise
fitness I-Premise
and I-Premise
fatigue I-Premise
with I-Premise
differences I-Premise
being I-Premise
observed I-Premise
between I-Premise
the I-Premise
treatment I-Premise
groups I-Premise
and I-Premise
the I-Premise
UC I-Premise
group I-Premise
. I-Premise

The B-Premise
SCNS I-Premise
physical I-Premise
and I-Premise
patient I-Premise
care I-Premise
subscales I-Premise
( I-Premise
-14.2 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
-26.2 I-Premise
to I-Premise
-2.2 I-Premise
";" I-Premise
P I-Premise
= I-Premise
0.02 I-Premise
and I-Premise
-7.4 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
-13.7 I-Premise
to I-Premise
-1.1 I-Premise
";" I-Premise
P I-Premise
= I-Premise
0.02 I-Premise
, I-Premise
respectively I-Premise
) I-Premise
and I-Premise
self-reported I-Premise
health I-Premise
state I-Premise
( I-Premise
12.8 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
3.2 I-Premise
to I-Premise
22.4 I-Premise
";" I-Premise
P I-Premise
= I-Premise
0.01 I-Premise
) I-Premise
also I-Premise
differed I-Premise
significantly I-Premise
. I-Premise

Multicenter O
, O
randomized O
trial O
. O

Moreover O
, O
these B-Claim
two I-Claim
treatment I-Claim
protocols I-Claim
are I-Claim
inefficient I-Claim
and I-Claim
cost I-Claim
time I-Claim
in I-Claim
application I-Claim
. I-Claim

Cross-sectional B-Premise
analyses I-Premise
( I-Premise
corrected I-Premise
for I-Premise
multiple I-Premise
testing I-Premise
) I-Premise
identified I-Premise
statistically I-Premise
significant I-Premise
differences I-Premise
that I-Premise
favored I-Premise
orchiectomy I-Premise
plus I-Premise
placebo I-Premise
for I-Premise
two I-Premise
of I-Premise
the I-Premise
five I-Premise
primary I-Premise
QOL I-Premise
parameters I-Premise
as I-Premise
follows I-Premise
: I-Premise
patients I-Premise
receiving I-Premise
flutamide I-Premise
reported I-Premise
more I-Premise
diarrhea I-Premise
at I-Premise
3 I-Premise
months I-Premise
( I-Premise
P I-Premise
= I-Premise
.001 I-Premise
) I-Premise
and I-Premise
worse I-Premise
emotional I-Premise
functioning I-Premise
at I-Premise
3 I-Premise
and I-Premise
6 I-Premise
months I-Premise
( I-Premise
both I-Premise
P I-Premise
< I-Premise
.003 I-Premise
) I-Premise
. I-Premise

Facial B-Claim
hirsutism I-Claim
is I-Claim
one I-Claim
of I-Claim
the I-Claim
characteristic I-Claim
features I-Claim
of I-Claim
polycystic I-Claim
ovary I-Claim
syndrome I-Claim
( I-Claim
PCOS I-Claim
) I-Claim
, I-Claim
and I-Claim
this I-Claim
can I-Claim
lead I-Claim
to I-Claim
high I-Claim
levels I-Claim
of I-Claim
depression I-Claim
and I-Claim
anxiety I-Claim
. I-Claim

Hormone B-Claim
replacement I-Claim
therapy I-Claim
is I-Claim
often I-Claim
either I-Claim
undesirable I-Claim
or I-Claim
contraindicated I-Claim
. I-Claim

Of O
131 O
patients O
in O
the O
larger O
randomized O
controlled O
study O
, O
we O
report O
data O
on O
54 O
evaluable O
patients O
( O
16 O
older O
adults O
and O
38 O
younger O
adults O
) O
randomized O
to O
the O
intervention O
. O

A O
phase O
III O
study O
to O
definitively O
test O
this O
neoadjuvant-concurrent O
strategy O
is O
warranted O
. O

The O
trial O
was O
designed O
to O
use O
one-sided O
tests O
of O
significance O
for O
power O
calculations O
, O
but O
is O
now O
reported O
with O
both O
one-sided O
and O
the O
traditional O
two-sided O
tests O
of O
significance O
. O

Overall B-Premise
response I-Premise
was I-Premise
54 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
CI I-Premise
] I-Premise
44.1 I-Premise
% I-Premise
-63.9 I-Premise
% I-Premise
) I-Premise
with I-Premise
PVI I-Premise
5-FU I-Premise
+ I-Premise
MMC I-Premise
compared I-Premise
to I-Premise
38 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
: I-Premise
28.3 I-Premise
% I-Premise
-47.7 I-Premise
% I-Premise
) I-Premise
for I-Premise
PVI I-Premise
5-FU I-Premise
alone I-Premise
( I-Premise
P I-Premise
= I-Premise
0.024 I-Premise
) I-Premise
. I-Premise

Dietary O
intake O
( O
protein O
, O
energy O
, O
fiber O
) O
assessed O
at O
baseline O
and O
at O
4 O
, O
8 O
, O
and O
12 O
weeks O
after O
starting O
radiotherapy O
. O

In B-Premise
grade I-Premise
IV I-Premise
tumours I-Premise
the I-Premise
corresponding I-Premise
figures I-Premise
were I-Premise
5.1 I-Premise
and I-Premise
3.3 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
. I-Premise

The B-Claim
oral I-Claim
regimen I-Claim
also I-Claim
can I-Claim
be I-Claim
safely I-Claim
given I-Claim
with I-Claim
appropriate I-Claim
toxicity I-Claim
and I-Claim
tolerability I-Claim
. I-Claim

Thyroid B-Premise
ablation I-Premise
was I-Premise
complete I-Premise
in I-Premise
631 I-Premise
of I-Premise
the I-Premise
684 I-Premise
patients I-Premise
( I-Premise
92 I-Premise
% I-Premise
) I-Premise
. I-Premise

IFNalpha O
was O
administered O
three O
times O
a O
week O
at O
a O
dose O
of O
3 O
million O
units O
subcutaneously O
for O
24 O
months O
. O

To O
compare O
the O
effectiveness O
and O
tolerability O
of O
gemcitabine O
plus O
cisplatin O
with O
single-agent O
gemcitabine O
as O
first-line O
chemotherapy O
for O
locally O
advanced O
or O
metastatic O
pancreatic O
cancer O
. O

This O
open-label O
study O
was O
designed O
to O
compare O
the O
overall O
survival O
( O
OS O
) O
of O
patients O
randomly O
assigned O
to O
GEM O
alone O
or O
GEM O
plus O
capecitabine O
( O
GEM-CAP O
) O
. O

The O
EG O
participants O
kept O
home O
practice O
diaries O
. O

Ten O
common O
symptoms O
were O
assessed O
by O
self-report O
questionnaire O
administered O
to O
1,614 O
consecutive O
patients O
at O
baseline O
and O
every O
3 O
months O
during O
the O
first O
year O
of O
a O
double-blind O
, O
randomized O
trial O
of O
postmenopausal O
women O
with O
early O
hormone O
receptor-positive O
breast O
cancer O
. O

Seventy-five O
patients O
with O
good O
performance O
status O
entered O
the O
trial O
. O

Median B-Premise
PFS I-Premise
and I-Premise
OS I-Premise
were I-Premise
8.2 I-Premise
and I-Premise
19.8 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
, I-Premise
at I-Premise
median I-Premise
follow-up I-Premise
of I-Premise
26.4 I-Premise
months I-Premise
. I-Premise

Swallowing B-Premise
and I-Premise
coughing I-Premise
problems I-Premise
decreased I-Premise
more I-Premise
in I-Premise
the I-Premise
TPF I-Premise
arm I-Premise
than I-Premise
in I-Premise
the I-Premise
PF I-Premise
arm I-Premise
at I-Premise
the I-Premise
end I-Premise
of I-Premise
cycle I-Premise
2 I-Premise
, I-Premise
but B-Premise
to I-Premise
a I-Premise
limited I-Premise
extent I-Premise
. I-Premise

Relatively O
small O
patient O
population O
. O

Subjects O
were O
88 O
women O
with O
facial O
hirsutism O
due O
to O
PCOS O
recruited O
from O
hospital O
outpatient O
clinics O
and O
a O
patient O
support O
group O
in O
2001-2002 O
. O

Severe B-Premise
rash I-Premise
occurred I-Premise
in I-Premise
9 I-Premise
% I-Premise
and I-Premise
severe I-Premise
diarrhea I-Premise
in I-Premise
6 I-Premise
% I-Premise
of I-Premise
erlotinib-treated I-Premise
patients I-Premise
and I-Premise
each I-Premise
resulted I-Premise
in I-Premise
study I-Premise
discontinuation I-Premise
in I-Premise
1 I-Premise
% I-Premise
of I-Premise
patients I-Premise
. I-Premise

Breast O
intensity-modulated O
radiation O
therapy O
( O
IMRT O
) O
is O
a O
technique O
that O
ensures O
a O
more O
homogeneous O
dose O
distribution O
. O

The O
EORTC O
24971/TAX O
323 O
, O
a O
phase O
III O
study O
of O
358 O
patients O
with O
unresectable O
locoregionally O
advanced O
squamous O
cell O
carcinoma O
of O
the O
head O
and O
neck O
, O
showed O
an O
improved O
progression-free O
and O
overall O
survival O
( O
OS O
) O
with O
less O
toxicity O
when O
docetaxel O
( O
T O
) O
was O
added O
to O
cisplatin O
and O
5-fluorouracil O
( O
PF O
) O
for O
induction O
and O
given O
before O
radiotherapy O
( O
RT O
) O
. O

The O
secondary O
end O
points O
were O
morbidity O
, O
QOL O
, O
and O
functional O
outcome O
. O

The O
treatments O
were O
repeated O
every O
3 O
weeks O
for O
six O
cycles O
";" O
in O
responding O
patients O
, O
an O
additional O
three O
cycles O
of O
single-agent O
carboplatin O
was O
permitted O
. O

Overall B-Premise
objective I-Premise
response I-Premise
( I-Premise
OR I-Premise
) I-Premise
rates I-Premise
were I-Premise
higher I-Premise
in I-Premise
patients I-Premise
treated I-Premise
with I-Premise
EXE I-Premise
than I-Premise
in I-Premise
those I-Premise
treated I-Premise
with I-Premise
MA I-Premise
( I-Premise
15.0 I-Premise
% I-Premise
v I-Premise
12.4 I-Premise
% I-Premise
) I-Premise
";" I-Premise
a B-Premise
similar I-Premise
trend I-Premise
was I-Premise
noted I-Premise
in I-Premise
patients I-Premise
with I-Premise
visceral I-Premise
metastases I-Premise
( I-Premise
13.5 I-Premise
% I-Premise
v I-Premise
10.5 I-Premise
% I-Premise
) I-Premise
. I-Premise

Likewise O
, O
emotional B-Premise
, I-Premise
functional I-Premise
well-being I-Premise
, I-Premise
and I-Premise
QoL I-Premise
aspects I-Premise
specifically I-Premise
related I-Premise
to I-Premise
lung I-Premise
cancer I-Premise
were I-Premise
better I-Premise
improved I-Premise
in I-Premise
the I-Premise
Gefitinib I-Premise
group I-Premise
than I-Premise
in I-Premise
the I-Premise
Pemetrexed I-Premise
group I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

Evidence B-Premise
of I-Premise
a I-Premise
homeopathic I-Premise
" I-Premise
drug I-Premise
proving I-Premise
" I-Premise
in I-Premise
the I-Premise
subjects I-Premise
receiving I-Premise
the I-Premise
homeopathic I-Premise
combination I-Premise
medicine I-Premise
who I-Premise
were I-Premise
not I-Premise
taking I-Premise
tamoxifen I-Premise
also I-Premise
was I-Premise
found I-Premise
. I-Premise

The B-Premise
SF-36 I-Premise
MCS I-Premise
and I-Premise
PCS I-Premise
, I-Premise
Health I-Premise
Utilities I-Premise
Index I-Premise
Mark I-Premise
3 I-Premise
, I-Premise
EuroQol I-Premise
5D I-Premise
, I-Premise
and I-Premise
UDI I-Premise
scores I-Premise
were I-Premise
improved I-Premise
significantly I-Premise
in I-Premise
both I-Premise
groups I-Premise
at I-Premise
6 I-Premise
months I-Premise
and I-Premise
afterward I-Premise
( I-Premise
P I-Premise
< I-Premise
.05 I-Premise
) I-Premise
. I-Premise

Overall O
278 O
patients O
were O
enrolled O
into O
the O
trial O
. O

There O
were O
no O
differences O
between O
treatment O
groups O
in O
dimension O
scores O
at O
baseline O
( O
randomization O
) O
. O

Chemotherapy O
was O
first-line O
or O
second-line O
for O
MBC O
. O

The B-Premise
major I-Premise
World I-Premise
Health I-Premise
Organization I-Premise
grade I-Premise
3-4 I-Premise
toxicities I-Premise
for I-Premise
NP I-Premise
and I-Premise
NIP I-Premise
, I-Premise
respectively I-Premise
, I-Premise
were I-Premise
: I-Premise
neutropenia I-Premise
( I-Premise
20.3 I-Premise
% I-Premise
compared I-Premise
with I-Premise
9 I-Premise
% I-Premise
of I-Premise
cycles I-Premise
) I-Premise
, I-Premise
anaemia I-Premise
( I-Premise
4.1 I-Premise
% I-Premise
compared I-Premise
with I-Premise
5 I-Premise
% I-Premise
of I-Premise
cycles I-Premise
) I-Premise
, I-Premise
nausea I-Premise
and I-Premise
vomiting I-Premise
( I-Premise
22.2 I-Premise
% I-Premise
compared I-Premise
with I-Premise
19.4 I-Premise
% I-Premise
of I-Premise
patients I-Premise
) I-Premise
and I-Premise
alopecia I-Premise
( I-Premise
5.6 I-Premise
% I-Premise
compared I-Premise
with I-Premise
29.8 I-Premise
% I-Premise
of I-Premise
patients I-Premise
) I-Premise
. I-Premise

From O
January O
2002 O
to O
February O
2004 O
, O
102 O
patients O
who O
had O
undergone O
RP O
for O
localized O
or O
locally O
advanced O
prostate O
cancer O
were O
recruited O
and O
randomized O
into O
3 O
groups O
, O
namely O
group O
1-those O
receiving O
only O
150 O
mg O
bicalutamide O
as O
adjuvant O
hormonal O
therapy O
, O
group O
2-those O
receiving O
bicalutamide O
and O
10 O
mg O
tamoxifen O
, O
and O
group O
3-those O
receiving O
bicalutamide O
and O
RT O
. O

The O
primary O
outcome O
measures O
were O
dysphagia O
, O
quality O
of O
life O
( O
QL O
) O
6 O
weeks O
following O
treatment O
, O
and O
total O
cost O
of O
treatment O
. O

Patients O
( O
n O
= O
739 O
) O
with O
stage O
M1 O
( O
bone O
or O
soft O
tissue O
metastasis O
) O
prostate O
cancer O
were O
enrolled O
in O
a O
QOL O
protocol O
that O
was O
a O
companion O
to O
Southwest O
Oncology O
Group O
INT-0105 O
, O
a O
randomized O
double-blind O
trial O
comparing O
treatment O
with O
bilateral O
orchiectomy O
( O
surgical O
castration O
) O
plus O
either O
flutamide O
or O
placebo O
. O

Measurements O
were O
performed O
before O
( O
T0 O
) O
and O
after O
the O
rehabilitation O
program O
( O
T1 O
) O
, O
and O
at O
a O
3-month O
follow-up O
( O
T2 O
) O
. O

We O
explored O
the O
quality O
of O
life O
( O
QoL O
) O
of O
such O
patients O
in O
a O
multicenter O
randomized O
trial O
that O
compared O
vinorelbine O
treatment O
with O
supportive O
care O
alone O
. O

Of O
those O
, O
34 O
consented O
to O
random O
assignment O
, O
62 O
chose O
RP O
, O
and O
94 O
chose O
BT O
. O

During O
the O
3-day O
efficacy O
phase O
, O
patients O
received O
placebo O
or O
1-3 O
tablets O
of O
oxycodone/paracetamol O
( O
5/325 O
mg O
) O
, O
four O
times O
daily O
for O
3 O
days O
. O

Intention-to-treat B-Premise
analyses I-Premise
indicated I-Premise
that I-Premise
AET I-Premise
resulted I-Premise
in I-Premise
a I-Premise
nonsignificant I-Premise
( I-Premise
P I-Premise
= I-Premise
0.16 I-Premise
) I-Premise
improvement I-Premise
in I-Premise
global I-Premise
sleep I-Premise
quality I-Premise
compared I-Premise
with I-Premise
usual I-Premise
care I-Premise
[ I-Premise
mean I-Premise
group I-Premise
difference I-Premise
= I-Premise
-0.64 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
( I-Premise
CI I-Premise
) I-Premise
, I-Premise
-1.56 I-Premise
to I-Premise
+0.27 I-Premise
] I-Premise
. I-Premise

Care O
closer O
to O
home O
is O
being O
explored O
as O
a O
means O
of O
improving O
patient O
experience O
as O
well O
as O
efficiency O
in O
terms O
of O
cost O
savings O
. O

The O
KS O
Functional O
Assessment O
of O
HIV O
( O
FAHI O
) O
quality O
of O
life O
instrument O
was O
used O
before O
and O
after O
every O
other O
treatment O
cycle O
. O

This O
is O
a O
randomized O
phase O
II O
study O
designed O
to O
compare O
the O
toxicity O
profile O
of O
a O
non-platinum-based O
with O
a O
platinum-based O
regimen O
in O
the O
treatment O
of O
advanced O
non-small O
cell O
lung O
cancer O
. O

At B-Premise
the I-Premise
six I-Premise
month I-Premise
follow-up I-Premise
, I-Premise
most I-Premise
of I-Premise
these I-Premise
effects I-Premise
were I-Premise
maintained I-Premise
and I-Premise
an I-Premise
intervention I-Premise
effect I-Premise
for I-Premise
breast I-Premise
cancer I-Premise
specific I-Premise
quality I-Premise
of I-Premise
life I-Premise
emerged I-Premise
. I-Premise

There O
were O
no O
statistically O
significant O
differences O
for O
ED O
. O

However B-Premise
, I-Premise
1-month I-Premise
GI I-Premise
toxicity I-Premise
was I-Premise
not I-Premise
only I-Premise
worse I-Premise
in I-Premise
patients I-Premise
with I-Premise
the I-Premise
hypofractionated I-Premise
RT I-Premise
schedule I-Premise
but I-Premise
also I-Premise
adversely I-Premise
affected I-Premise
daily I-Premise
activities I-Premise
. I-Premise

